WO2021150258A1 - Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same - Google Patents
Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same Download PDFInfo
- Publication number
- WO2021150258A1 WO2021150258A1 PCT/US2020/025522 US2020025522W WO2021150258A1 WO 2021150258 A1 WO2021150258 A1 WO 2021150258A1 US 2020025522 W US2020025522 W US 2020025522W WO 2021150258 A1 WO2021150258 A1 WO 2021150258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding peptide
- peptide conjugate
- compound
- isotopically labelled
- formula
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 61
- 239000000863 peptide conjugate Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 35
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 184
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract description 100
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract description 99
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 238000003384 imaging method Methods 0.000 claims abstract description 16
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 68
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 125000000524 functional group Chemical group 0.000 claims description 44
- -1 Pentastatin Chemical compound 0.000 claims description 37
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 29
- 229910052805 deuterium Inorganic materials 0.000 claims description 28
- 229910052722 tritium Inorganic materials 0.000 claims description 28
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 27
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 26
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical class OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 23
- 235000018417 cysteine Nutrition 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 125000004434 sulfur atom Chemical group 0.000 claims description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 14
- 229960001592 paclitaxel Drugs 0.000 claims description 14
- 230000002285 radioactive effect Effects 0.000 claims description 12
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical class OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 229960001639 penicillamine Drugs 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 230000000155 isotopic effect Effects 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 5
- 102000015790 Asparaginase Human genes 0.000 claims description 5
- 108010024976 Asparaginase Proteins 0.000 claims description 5
- 108010006654 Bleomycin Proteins 0.000 claims description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 5
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 5
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 5
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- 229930192392 Mitomycin Natural products 0.000 claims description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 5
- 229960000473 altretamine Drugs 0.000 claims description 5
- 229960003272 asparaginase Drugs 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 5
- 229960001561 bleomycin Drugs 0.000 claims description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 229960005243 carmustine Drugs 0.000 claims description 5
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004630 chlorambucil Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229960002436 cladribine Drugs 0.000 claims description 5
- 239000002872 contrast media Substances 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- 229960003901 dacarbazine Drugs 0.000 claims description 5
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 5
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 5
- 229960003649 eribulin Drugs 0.000 claims description 5
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims description 5
- 229930182833 estradiol Natural products 0.000 claims description 5
- 229960005309 estradiol Drugs 0.000 claims description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 5
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 5
- 229960004857 mitomycin Drugs 0.000 claims description 5
- 229960000350 mitotane Drugs 0.000 claims description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 5
- 229960001156 mitoxantrone Drugs 0.000 claims description 5
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims description 5
- 229960000952 pipobroman Drugs 0.000 claims description 5
- 229960003171 plicamycin Drugs 0.000 claims description 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
- 229960004618 prednisone Drugs 0.000 claims description 5
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000624 procarbazine Drugs 0.000 claims description 5
- 229960001052 streptozocin Drugs 0.000 claims description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 5
- 229960001603 tamoxifen Drugs 0.000 claims description 5
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 5
- 229960001278 teniposide Drugs 0.000 claims description 5
- 229960003048 vinblastine Drugs 0.000 claims description 5
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 5
- 229960004528 vincristine Drugs 0.000 claims description 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 150000001945 cysteines Chemical class 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 96
- 239000000203 mixture Substances 0.000 abstract description 35
- 239000012216 imaging agent Substances 0.000 abstract description 16
- 230000002018 overexpression Effects 0.000 abstract description 12
- 239000000032 diagnostic agent Substances 0.000 abstract description 8
- 229940039227 diagnostic agent Drugs 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 208000031886 HIV Infections Diseases 0.000 abstract description 5
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 5
- 238000012377 drug delivery Methods 0.000 abstract description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 5
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 230000003827 upregulation Effects 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 158
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 86
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000011347 resin Substances 0.000 description 50
- 229920005989 resin Polymers 0.000 description 50
- 239000000243 solution Substances 0.000 description 47
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 38
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 32
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 28
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 28
- 238000003776 cleavage reaction Methods 0.000 description 27
- 230000007017 scission Effects 0.000 description 26
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
- 125000005647 linker group Chemical group 0.000 description 23
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 22
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 17
- 229910001868 water Inorganic materials 0.000 description 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 238000001994 activation Methods 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 16
- 229920001223 polyethylene glycol Polymers 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 150000001408 amides Chemical class 0.000 description 14
- 125000003277 amino group Chemical group 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 238000010511 deprotection reaction Methods 0.000 description 13
- 238000004949 mass spectrometry Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 230000004224 protection Effects 0.000 description 13
- 238000007363 ring formation reaction Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000004472 Lysine Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 10
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 6
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000001099 ammonium carbonate Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- LOBUWFUSGOYXQX-DHUJRADRSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(4-methoxyphenyl)-diphenylmethyl]sulfanylpropanoic acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)SC[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 LOBUWFUSGOYXQX-DHUJRADRSA-N 0.000 description 5
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 5
- 159000000021 acetate salts Chemical class 0.000 description 5
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 5
- 230000021736 acetylation Effects 0.000 description 5
- 238000006640 acetylation reaction Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 150000001944 cysteine derivatives Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- LUGFCMICCJNLBC-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonyl-propan-2-ylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCN(C(C)C)C(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 LUGFCMICCJNLBC-VWLOTQADSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 125000006242 amine protecting group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 125000001151 peptidyl group Chemical group 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 3
- JYUTZJVERLGMQZ-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-naphthalen-2-ylpropanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CC=C(C=CC=C2)C2=C1 JYUTZJVERLGMQZ-SANMLTNESA-N 0.000 description 3
- FKBGJLDYRSFHBT-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-tritylsulfanylbutanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CSC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 FKBGJLDYRSFHBT-DHUJRADRSA-N 0.000 description 3
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 3
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 3
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 125000002228 disulfide group Chemical group 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ATAFDSCDEDHMOK-UHFFFAOYSA-N 3,3-diaminopropanoic acid Chemical compound NC(N)CC(O)=O ATAFDSCDEDHMOK-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- OWSRLHPWDZOHCR-UHFFFAOYSA-N 4,4-diaminobutanoic acid Chemical compound NC(N)CCC(O)=O OWSRLHPWDZOHCR-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N deuterated acetone Substances [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004220 glutamic acid Chemical group 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000002835 hiv fusion inhibitor Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical class OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PCZHWPSNPWAQNF-LMOVPXPDSA-K 2-[[(2s)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron Chemical compound [Gd+3].CCOC1=CC=C(C[C@@H](CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)N(CC(O)=O)CC([O-])=O)C=C1 PCZHWPSNPWAQNF-LMOVPXPDSA-K 0.000 description 1
- NFPWGFSRWDHFFT-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid gadolinium Chemical compound [Gd].CNC(=O)CN(CCN(CCN(CC(O)=O)CC(=O)NC)CC(O)=O)CC(O)=O NFPWGFSRWDHFFT-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- AUDYZXNUHIIGRB-UHFFFAOYSA-N 3-thiophen-2-ylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2SC=CC=2)=C1 AUDYZXNUHIIGRB-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101150071882 US17 gene Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical group CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- HKGATZAPXCCEJR-OWRSNIELSA-N [4-[[(2s)-2-[[(2s)-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]propanoyl]amino]phenyl]methyl (6s,6as)-3-[5-[[(6as)-2-methoxy-8-methyl-1 Chemical compound N([C@H](C(=O)N[C@@H](C)C(=O)NC1=CC=C(C=C1)COC(=O)N1C=2C=C(C(=CC=2C(=O)N2C=C(C)C[C@H]2[C@@H]1O)OC)OCCCCCOC1=CC2=C(C(N3C=C(C)C[C@H]3C=N2)=O)C=C1OC)C(C)C)C(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O HKGATZAPXCCEJR-OWRSNIELSA-N 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- OAOPDYUHWPBJCW-UHFFFAOYSA-N cyanoboron;sodium Chemical compound [Na].[B]C#N OAOPDYUHWPBJCW-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical group OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- MXZROTBGJUUXID-UHFFFAOYSA-K gadobenic acid Chemical compound [H+].[H+].[Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-K 0.000 description 1
- 229960003411 gadobutrol Drugs 0.000 description 1
- 229960005063 gadodiamide Drugs 0.000 description 1
- PIZALBORPSCYJU-QSQMUHTISA-H gadofosveset Chemical compound O.[Na+].[Na+].[Na+].[Gd+3].C1CC(OP([O-])(=O)OC[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC(=O)[O-])N(CC([O-])=O)CC([O-])=O)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 PIZALBORPSCYJU-QSQMUHTISA-H 0.000 description 1
- 229960003935 gadofosveset Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
- 229940005649 gadopentetate Drugs 0.000 description 1
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 1
- 229960005451 gadoteridol Drugs 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 229960002059 gadoversetamide Drugs 0.000 description 1
- 229940097926 gadoxetate Drugs 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical group OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003084 hiv integrase inhibitor Substances 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 102000053523 human CXCR4 Human genes 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108010093470 monomethyl auristatin E Proteins 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- DRKHJSDSSUXYTE-UHFFFAOYSA-L oxidanium;2-[bis[2-[carboxylatomethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [OH3+].[Gd+3].COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC DRKHJSDSSUXYTE-UHFFFAOYSA-L 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical group OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229930184737 tubulysin Natural products 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Definitions
- the present invention relates to an isotopically labelled selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same.
- the isotopically labelled selective CXCR4 binding peptide conjugate of the invention is isoptocially labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium,
- 13 C, 14 C, 18 0, or a combination thereof comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound.
- a medically useful compound such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound.
- CXCL12 also called stromal cell-derived factor-1 or SDF-1
- CXCR4 a chemokine and chemokine receptor pair play important roles in hematopoiesis, multiple stages of tumorigenesis, and embryonic development.
- CXCR4 activation of CXCR4 by CXCL12 has shown to direct leukocyte chemotaxis in the immune system in response to inflammation and progenitor cell migration during embryologic development.
- Activation of CXCR4 by CXCL12 has also been shown to mediate signaling pathway that is involved in breast cancer metastasis and memory T cell migration.
- CXCR4 a G-protein-coupled receptor also known as fusion or CD 184 (cluster of differentiation 184), is constitutively- or over-expressed in a wide variety of human cancers, promoting local tumor cell proliferation, survival and angiogenesis. It has also been reported that CXCR4 is a co-receptor for HIV entry and infection of host cells and has been evaluated as a potential HIV therapy.
- CXCR4 is overexpressed in numerous human cancers.
- CXCR4 antagonism has been shown to disrupt tumor-stromal interactions, sensitize cancer cells to cytotoxic drugs, and reduce tumor growth and metastatic burden.
- CXCR4 is a target not only for potential therapeutic intervention of cancer treatment, but also for noninvasive monitoring of disease progression, therapeutic guidance, and other diagnostic purposes. Some have even suggested that binding and interacting with CXCR4 as a potential way of targeted drug delivery.
- CXCR4 i.e., CXCR4 selective binding conjugate
- CXCR4 selective binding conjugate can have a wide variety uses including, but not limited to, treating a wide array of clinical conditions associated with activation or over expression of CXCR4, diagnosing a patient, and medical imaging.
- CXCR4 can study the various mode of drug delivery, drug interaction, diagnosis, in vivo imaging of cells affected by over-expression of CXCR4, etc. It would be more useful, if such a labelled compound does not significantly alter the interaction with CXCR4.
- conjugates that can selectively bind to CXCR4 having a medically useful compound.
- a labelled conjugate that does not significantly alter the physical properties, such as a binding constant, drug activity, its three-dimensional structure, etc.
- the present invention provides an isotopically labelled selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same.
- the selective CXCR4 binding peptide conjugate of the invention is isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13 C, 14 C, 18 0, and/or a combination thereof deuterium, tritium, 13 C, 14 C, 18 0, or a combination thereof, and comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound.
- a medically useful compound such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound.
- the peptidyl portion of the compounds of the invention is isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13 C, 14 C, 18 0, or a combination thereof. In this manner, one can readily trace, image, or study the compounds in vivo.
- the peptide or peptidyl portion is linked to the medically useful compound via a polymeric linker.
- the peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery, imaging a patient, studying the medically useful compound in vivo (e.g., interaction with CXCR4, etc.), diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.
- a targeted drug delivery e.g., imaging a patient
- studying the medically useful compound in vivo e.g., interaction with CXCR4, etc.
- diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders e.g., cancers, HIV infection, and immune disorders.
- Compositions, kits and methods are also disclosed herein for such uses.
- PC CXCR4 binding peptide conjugate
- AA 1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, optionally substituted homocysteine, or optionally substituted penicillamine;
- Ar 1 is an optionally substituted aryl
- X 1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); each of AA 3 is independently Gly, Phe, 2Nal, INal, Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr); and wherein at least one of AA 1 , X 1 , AA 2 , or AA 3 comprises a moiety of the formula:
- L 1 is a polymeric linker having a functional group for linking Q, wherein L 1 comprises from about 2 to about 20 monomers or copolymers;
- Q is absent, AA 4 , or a moiety of the formula: -[AA 4 -Y 1 -L 2 ] C- Y 2 -Z, wherein c is 0 or 1;
- AA 4 is an amino acid or a derivative thereof
- Y 1 is a side-chain function group of amino acid AA 4 ;
- L 2 is a non-polymeric linker
- Z a medically useful compound
- Y 2 is a functional group of said medically useful compound or a functional group of L 2 ; and wherein one or more of AA 1 , AA 2 , X 1 , AA 3 , and AA 4 are isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13 C, 14 C, 18 0, or a combination thereof.
- the medically useful compounds that can be used in the invention include, but are not limited to, compounds that can be used in diagnosis, treatment, or assaying various clinical conditions.
- Exemplary medically useful compounds include, but are not limited, imaging agents, contrast agents, and therapeutic agents (e.g., drugs).
- the selective CXCR4 binding peptide conjugate of the invention is of the formula:
- Q is absent from compounds of formulas disclosed herein.
- At least one of AA 1 , X 1 , AA 2 , or AA 3 comprises a moiety of the formula -L 1 .
- Such a compound can be used as a starting material for attaching or linking AA 4 ,
- Q is AA 4 .
- Such a compound can be used for attaching or linking a moiety of the formula -Y'-L 2 -Y 2 -Z.
- Q is a moiety of the formula: -[AA 4 -Y 1 -L 2 ] C- Y 2 -Z.
- the invention provides both starting materials for attaching a medically useful compound as well as selective CXCR4 binding peptide conjugates that include at least one medically useful compound.
- a is 0. Still in other embodiments, a is 1.
- At least one of X 1 and AA 3 is isotopically labelled.
- both X 1 and AA 3 are isotopically labelled.
- Exemplary isotopic labels include, but are not limited to, deuterium, tritium, 13 C, 14 C, 18 0, and a combination thereof.
- isotopic label comprises deuterium or tritium.
- the isotopically labelled X 1 and/or AA 3 comprises deuterium, tritium, 13 C, 14 C, 18 0, or a combination thereof.
- at least one of X 1 and AA 3 is isotopic labelled with deuterium or tritium.
- X 1 and AA 3 are isotopically labelled Lys(iPr). More specifically, in one embodiment, X 1 and AA 3 are both Lys(deuterated iPr).
- the medically useful compound is a therapeutic agent.
- the therapeutic agent is an anticancer agent.
- anticancer agents that can be used in the invention include, but are not limited to, paclitaxel, Altretamine, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, dacarbazine, Diethylstilbestrol, Eribulin, Ethinyl, estradiol, Etoposide, Mitomycin, Mitotane, Mitoxantrone, Pentastatin, Pipobroman, Plicamycin, Prednisone, Procarbazine, Streptozocin, Tamoxifen, Teniposide, Vinblastine, and Vincristine.
- any anticancer agent that has a functional group suitable for linkage can be used.
- any anticancer agent that has a functional group suitable for linkage can
- the isotopically labelled selective CXCR4 binding peptide conjugate of the invention of the formula:
- L la is a polymeric linker comprising from about 2 to about 20 monomers or copolymers.
- L 2 is a non-polymeric linker of the formula:
- AA 1 along with the sulfur atom that is attached thereto is optionally substituted cysteine or optionally substituted homocysteine.
- the a- amino group of AA 1 can be substituted with an acyl group (e.g., acetyl group, etc.), alkyl group (e.g., methyl, dimethyl, ethyl, dimethyl, propyl, dipropyl, iso-propyl, di(iso-propyl), etc.), haloalkyl (e.g., trifluoromethyl, ditrifluoromethyl, etc.).
- acyl group e.g., acetyl group, etc.
- alkyl group e.g., methyl, dimethyl, ethyl, dimethyl, propyl, dipropyl, iso-propyl, di(iso-propyl), etc.
- haloalkyl e.g., trifluoromethyl, ditrifluoromethyl, etc.
- AA 2 along with the sulfur atom that is attached thereto can also be an optionally substituted cysteine or optionally substituted homocysteine.
- X 1 and/or at least one of AA 3 is Lys(iPr) or
- Lys(deuterated-iPr) When deuterated (e.g., “deuterated-iPr”), iso-propyl group (“iPr”) can have one or more hydrogen atom that is replaced with a deuterium. In some embodiments, at least 2, typically at least 3, often at least 4, more often at least 5 and most often at least 6 hydrogen atoms of iPr are replaced with deuterium atoms.
- a short hand notation for amino acids AA(X) refers to amino acid AA that is substituted with “X” on the side chain functional group.
- Lys(iPr) refers to lysine that is substituted with iso-propyl group on the amine functional group of lysine’s side chain.
- Ar 1 is phenyl.
- Ar 1 is of the formula:
- b is 1.
- AA 3 is Lys(iPr) or Lys(deuterated-iPr).
- L 1 is a polymeric linker of the formula:
- AA 4 is cysteine, homocysteine, or penicillin amine.
- At least one of AA 1 , X 1 , AA 2 , or AA 3 amino acid residue is a (D)-isomer.
- a is 0.
- AA 1 is homocysteine
- Exemplary selective CXCR4 binding peptide conjugates of the invention include, but are not limited to, Compound of Formula A, Compound of Formula B, Compound of Formula C, Compound of Formula D, Compound of Formula E, Compound of Formula F, Compound of Formula G, Compound of Formula H, Compound of Formula I, Compound of Formula J, Compound of Formula K, Compound of Formula L, Compound of Formula M, Compound of Formula N, Compound of Formula O, and Compound of Formula P, as well as the corresponding deuterium labelled compounds (i.e., -D12) and tritium labelled compounds (i.e., - T12).
- deuterium labelled compounds i.e., -D12
- tritium labelled compounds i.e., - T12
- Another aspect of the invention provides a method for treating a subject suffering from a cancer, said method comprising administering to the subject a therapeutically effective amount of a selective CXCR4 binding peptide conjugate disclosed herein, wherein said medically useful compound is an anticancer agent.
- anticancer agents used methods of the invention include, but are not limited to, paclitaxel, Altretamine, Asparaginase,
- methods of the invention provide treatment of cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, kidney cancer, brain cancer, blood cancer, leukemia, prostate cancer, ovarian cancer, and bladder cancer.
- CXCR4 plays an important role in immune and inflammatory responses in various diseases and disorders, including cancer, viral infections, as well as autoimmune pathologies such as rheumatoid arthritis.
- the present invention is based at least in part on reducing or preventing overexpression or activation of CXCR4 to treat, diagnose or image a clinical condition associated with CXCR4 overexpression and/or activation.
- overexpression and/or activation refers to expression of a gene above its normal (i.e., control) or baseline level and/or activation of CXCR4 above its normal, control or baseline level, respectively.
- normal baseline level
- control level refers to expression and/or activity level of CXCR4 in subject(s) that do not have a disease or a clinical condition associated with overexpression and/or activation of CXCR4, such as those disclosed herein.
- the baseline level can be a normal level, meaning the level in a sample from a normal subject that do not have a clinical condition associated with overexpression and/or activation (or activity) of CXCR4.
- the overexpression and/or activation of CXCR4 can also be determined by comparing the sample result with a positive control.
- the term “positive control” as used herein refers to a level of CXCR4 expression and/or activation (or activity) established in a sample from a subject or from a population of individuals, where the sample was believed, based on data from that sample, to have a disease or a clinical condition associated with overexpression and/or activation of CXCR4 (e.g., cancer, autoimmune disease such as rheumatoid arthritis and viral infection, such as HIV infection).
- a disease or a clinical condition associated with overexpression and/or activation of CXCR4 e.g., cancer, autoimmune disease such as rheumatoid arthritis and viral infection, such as HIV infection.
- the baseline level can be established from a previous sample from the subject being tested, so that the disease progression or regression of the subject can be monitored over time and/or the efficacy of treatment can be evaluated.
- Some aspects of the invention provide compounds that have a high affinity toward
- CXCR4 that is attached to a diagnostic agent, a therapeutic agent or an imaging agent, through a linker.
- Such compounds include a CXCR4 binding moiety and a medically active component (or simply “an active compound”).
- an active compound refers to a compound that is a therapeutically active, or can be used in diagnostic or imaging, or any other uses associated with treatment, diagnostic, imaging, analysis or other uses in clinical applications.
- the invention also provides methods for using the same, e.g., in targeted delivery of therapeutics to treat clinical conditions manifested by or associated with overexpression and/or activation of CXCR4, imaging (e.g., in vivo or in vitro ) cells associated with CRCR4, identifying cells overexpressing or cells having activated CXCR4, etc.
- the term “high affinity” or “selective” means the compound or the moiety that binds to CXCR4 has a binding constant (K b ) of about 10 nM or less, typically about 3 nM or less, and often 1 nM or less.
- the term “high affinity” or “selective” means the compound or the moiety that binds to CXCR4 has 50% binding inhibition concentration (IC50) of about 30 nM or less, typically about 10 nM or less and often about 3 nM or less.
- IC50 binding inhibition concentration
- Methods for determining binding constant and IC50 are well known to one skilled in the art. See, for example, commonly assigned U.S. provisional patent application numbers 62/384,132, filed September 6, 2016, and 62/505,064, filed May 11, 2017, and commonly assigned PCT patent application no. PCT/US17/50106, filed September 5, 2017, all of which are incorporated herein by reference in their entirety.
- the values K b and IC50 are determined using the CXCR4/ 125 I-SDF-la binding assay described in the above referenced provisional patent applications.
- the terms “about” and “approximately” are used interchangeably herein and refer to being within an acceptable error range for the particular value as determined by one of ordinary skill in the art. Such a value determination will depend at least in part on how the value is measured or determined, e.g., the limitations of the measurement system, i.e., the degree of precision required for a particular purpose. For example, the term “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, the term “about” when referring to a numerical value can mean ⁇ 20%, typically ⁇ 10%, often ⁇ 5% and more often ⁇ 1 % of the numerical value. In general, however, where particular values are described in the application and claims, unless otherwise stated, the term “about” means within an acceptable error range for the particular value, typically within one standard deviation.
- a high affinity or selective CXCR4 binding peptide conjugate is of the Formula:
- AA 1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine;
- AA 1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, optionally substituted homocysteine, or optionally substituted penicillamine;
- Ar 1 is an optionally substituted aryl
- X 1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); each of AA 3 is independently Gly, Phe, 2Nal, INal, Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr); and wherein at least one of AA 1 , X 1 , AA 2 , or AA 3 comprises a moiety of the formula:
- L 1 is a polymeric linker having a functional group for linking Q, wherein L 1 comprises from about 2 to about 20 monomers or copolymers;
- Q is absent, AA 4 , or a moiety of the formula: -[AA 4 -Y 1 -L 2 ] C- Y 2 -Z, wherein c is 0 or 1;
- AA 4 is an amino acid or a derivative thereof;
- Y 1 is a side-chain function group of amino acid AA 4 ;
- L 2 is a non-polymeric linker
- Y 2 is a functional group of said medically useful compound or a functional group of L 2 ; and wherein one or more of AA 1 , AA 2 , X 1 , AA 3 , and AA 4 are isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13 C, 14 C, 18 0, or a combination thereof.
- “Pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
- Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4- hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2 -hydroxy ethanesulfonic acid, benzen
- an amino acid means the side chain functional group of the amino acid or the a-amino group of the amino acid may be substituted, for example, by an alkyl (e.g., Ci-Cio alkyl) or a functional group protecting group, etc.
- an alkyl e.g., Ci-Cio alkyl
- a functional group protecting group e.g., a carboxylate
- optionally substituted or “derivative thereof’ includes those substituted with an alkyl, a nitrogen protecting group (e.g., acyl containing moieties), and/or a haloalkyl (e.g., trifluoromethyl, etc.).
- the terms “optionally substituted” and “derivatives thereof’ can include those that are optionally substituted on the sulfur atom or the a- amine functional group, such as those with alkyl, thiol or amine protecting group, etc.
- the term optionally substituted refers to substitution on the a- amine group.
- Exemplary substitutions on the a-amine group include, but are not limited to, alkyl group, and amine protecting group, as well as those other substituents known to one skilled in the art.
- Protecting group refers to a moiety that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis , 3 rd edition, John Wiley & Sons, New York, 1999, and Harrison and Harrison et ah, Compendium of Synthetic Organic Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996), which are incorporated herein by reference in their entirety.
- AA 4 is an amino acid or a derivative thereof, where AA 4 has a side-chain functional group Y 1 .
- This presence of the side chain functional group allows attaching linker L 2 to the amino acid AA 4 .
- the functional group Y 1 when attached to L 1 has one less hydrogen atom attached thereto.
- the side chain functional group is -ME, thus Y 1 when it is not linked to L 2 is -Mb and when it is linked to L 2 , Y 1 is -NH-.
- the number of hydrogen atom attached to or is present on Y 1 is omitted merely for brevity.
- side-chain functional group of any amino acid can be readily changed by one skilled in the art.
- the hydroxy side chain functional group of serine can be changed to an amine, carboxylic acid, or other functional groups by one skilled in the art using the known reaction procedures.
- amine side chain functional group (i.e., -Mb) of lysine can be changed to azide, -NH-N3, hydroxy, amide, phosphate, thiol, etc.
- X 1 is isotopically labelled. Still in another embodiment, AA 3 is isotopically labelled.
- X 1 and/or AA 3 are/is isotopically labelled.
- Isotopically labelled compound of Formula I can be used inter alia for imaging and/or diagnostic purposes.
- Exemplary isotopically labelled X 1 and/or AA 3 include those comprising a positron-emitting radioisotope such 34 C1, 45 Ti, 51 Mn, 61 Cu, 63 Zn, 68 Ga, n C, 13 N, 15 0, and 18 F.
- radioisotope typically such radioisotopes are complexed to X 1 and/or AA 3 via a complexing or coordinating agent. Suitable complexing or coordinating moieties are well known to one skilled in the art.
- Other useful isotopic labels include, but are not limited to, deuterium (D), tritium (T), 13 C, 14 C, 18 0, or a combination thereof.
- a useful imaging agent includes a radioactive metal isotope that is coordinated (i.e., chelated) to a chelating group.
- Particularly useful radioactive metal isotopes include technetium, rhenium, gallium, gadolinium, indium, copper and a combination thereof.
- Appropriate chelating groups for a particular radioactive metal isotope are well known to one skilled in the art. For example, ferrocene and its derivatives, ethylenediaminetetraacetic acid (“EDTA”), its derivatives, a peptidyl moiety Dap-Asp-Cys and its derivatives (see U.S. Pat. No. 7,128,893), and others known in the art.
- Yet another example of a useful imaging agent includes a contrasting agent.
- Contrasting agents are widely used, for example, in magnetic resonance imaging (MRI).
- MRI magnetic resonance imaging
- contrasting agents are known to one skilled in the art including gadobenate, gadobutrol, gadodiamide, gadofosveset, gadopentetate, gadoterate, gadoteridol, gadoversetamide, gadoxetate, and iron oxide.
- Still another example of a useful imaging agent includes a fluorescent dye, such as fluorenylmethyloxycarbonyl (FMOC) and its derivatives, an AlexaFluor dye, an Oregon Green dye, a fluoresceins, a BODIPY (boron-dipyrromethene) dye, a cyanine dye, a rhodamine dye, a Dy Light dye, and Texas Red.
- a fluorescent dye such as fluorenylmethyloxycarbonyl (FMOC) and its derivatives, an AlexaFluor dye, an Oregon Green dye, a fluoresceins, a BODIPY (boron-dipyrromethene) dye, a cyanine dye, a rhodamine dye, a Dy Light dye, and Texas Red.
- X 1 and/or AA 3 comprises (e.g., attached or linked to) a diagnostic agent, such as an imaging agent, an isotopic agent, or a radioactive agent.
- a diagnostic agent such as an imaging agent, an isotopic agent, or a radioactive agent.
- X 1 and/or AA 3 is isotopically labelled.
- X 1 and/or AA 3 is lysine that is substituted with isotopically labelled side-chain.
- side- chain or “side chain” when referring to an amino acid is used to describe the “R” group in the following formula: H 2 N-CH(R)-C0 2 H.
- Side chain for a given amino acid is well known to one skilled in the art, for example, the side chain or “R” for glycine is H, for serine it is a moiety of the formula -CFEOH, etc.
- X 1 and/or AA 3 is lysine in which the side chain functional group amine is substituted with an isotopically labelled alkyl group.
- isotopically labelled alkyl group means either the carbon or the hydrogen atom(s) in the alkyl group is replaced with a corresponding isotope such as 13 C and/or 14 C for carbon atom(s), or deuterium or tritium for hydrogen atom(s).
- the amine nitrogen of the lysine side chain functional group is isotopically labelled with 13 N.
- the carbonyl oxygen of the amino acid is isotopically labelled with 18 0.
- one or more carbon atoms in the amino acid X 1 and/or AA 3 is isotopically labelled with 13 C or 14 C.
- a-amino functional group of amino acid X 1 and/or AA 3 is isotopically labelled with 14 N.
- a-amino functional group of amino acid X 1 and/or AA 3 can be substituted with isotopically labelled group, such as isotopically labelled carbonyl group (e.g., 18 0, 13 C, 14 C labelled carbonyl group) or isotopically labelled alkyl group (e.g., D, T, 13 C, or 14 C).
- isotopically labelled group such as isotopically labelled carbonyl group (e.g., 18 0, 13 C, 14 C labelled carbonyl group) or isotopically labelled alkyl group (e.g., D, T, 13 C, or 14 C).
- X 1 and/or AA 3 is Lys(iPr) or D-Lys(iPr) where one or more, typically two or more, often three or more, more often four or more, still more often five or more and most often at least six hydrogen atoms on the iPr group is isotopically labelled (i.e., replaced with) with deuterium or tritium.
- the peptidyl group is linked to a medically useful compound of the formula Z by using the functional group “Y 2 ” that is present on the medically useful compound or alternatively that is present on linker L 2 .
- Such an attachment is well known and can be readily achieved by one skilled in the art.
- medically useful compound Z is modified such that a leaving group or other suitable bond forming agent is present in Z, e.g., if Y 2 is an amino group of L 2 , it can be used to displace a halide or other suitable leaving groups (e.g., mesylate, tosylate, etc.) or connect to a carbonyl group that is present in the medically useful compound Z to form an amine or amide linkage, respectively.
- a leaving group or other suitable bond forming agent e.g., if Y 2 is an amino group of L 2 , it can be used to displace a halide or other suitable leaving groups (e.g., mesylate, tosylate, etc.) or connect to a carbonyl group that is present in the medically useful compound Z to form an amine or amide linkage, respectively.
- Y 2 is a hydroxyl group, it can be used to displace a halide or other leaving group or connect to a carbonyl group that is present in the medically useful compound to form an ether or an ester, respectively.
- the function group Y 2 is present on the medically useful compound Z, then Y 2 can be used to attach linker L 2 .
- linker L 2 For example, by linking a hydroxyl or an amino group that is present on the medically useful compound to a carbonyl group that is present on the non- polymeric linker L 2 . In this manner, an ester or an amide bond can be formed, respectively, between the medically useful compound and linker L 2 .
- Other suitable functional groups for Y2 will be readily recognized by one skilled in the art having read to present disclosure.
- amino acid AA 4 is an amino acid having a side chain with a functional group -Y 1 . This allows attachment of linker L 2 to the heteroatom Y 1 .
- suitable amino acids AA 4 include, but are not limited to, serine, cysteine, lysine, arginine, aspartic acid, glutamine, glutamic acid, histidine, proline, threonine, tryptophan, tyrosine, and the like, as well as homologs or derivatives thereof, such as homocysteine, homoserine.
- AA 4 can also be a non-proteinogenic amino acid, a synthetic amino acid, or an “unnatural amino acid”, i.e., an amino acid that does not occur naturally but are well known to one skilled in the art, such as ornithine, 1,4-diaminobutyric acid (Dab), 1,3-diaminopropionic acid (Dap), penicillamine, etc.
- AA 4 is cysteine, homocysteine, or penicillamine.
- Y 1 is sulfur (e.g., thiol).
- AA 4 is serine, in which instances Y 1 is oxygen (e.g., a hydroxyl group).
- amino acids disclosed herein can be either (D)- or (L)- stereo configuration. In fact, in some embodiments, one or more amino acids are (D)-configuration. In this manner, in vivo stability of compound of Formula I can be greatly enhanced or increased. Typically, unless stated otherwise amino acids of the invention are proteinogenic amino acids.
- L 1 is a polymeric linker comprising from about 2 to about 20, typically from about 2 to about 15, often from about 2 to about 10, more often from about 2 to 8, and most often from about 5 to about 8 monomers or copolymers.
- Copolymer refers to a linker having two or more different monomeric units.
- a copolymer can be a polymer that is formed between ethylene glycol propylene glycol units; between ethylene glycol and vinyl alcohol units; between ethylene glycol and vinyl acetate units; as well as other copolymers that are well known to one skilled in the art.
- L 1 is a polyethylene glycol (“PEG”)
- PEG polyethylene glycol
- one end of the PEG that is attached to AA 3 can be functionalized as an amine so that it forms an amide bond with AA 3 .
- the end of the PEG that is attached to AA 3 is maintained as a hydroxyl group, then it forms an ester bond with AA 3 .
- hydroxyl group of PEG that is attached to AA 4 is oxidized to a carboxylic acid moiety, then it forms an amide group with the a-amino functional group of AA 4 .
- a leaving group e.g., tosylate, mesylate, halide, etc.
- it can form an amino linkage with the a-amino functional group of AA 4 by, e.g., a displacement reaction.
- a wide variety of methods are available for linking L 1 to AA 3 and AA 4 .
- L 1 is a polyethylene glycol in which the end attached to AA 3 is an amino group, thereby forming an amide bond with AA 3 .
- L 1 is a polyethylene glycol in which the end that is attached to AA 4 is oxidized to a carboxylic acid or similar functional group, thereby forming an amide linkage with the a-amino functional group of amino acid AA 4 .
- a is 1.
- AA 3 is lysine or a derivative thereof (e.g., the amino group of the side chain is alkylated, acylated, or substituted with an amine protecting group) that is optionally isotopically labelled.
- the side chain amino functional group is alkylated with an alkyl group optionally having one or more deuterium or tritium in lieu of hydrogen on the alkyl group.
- the side chain amino functional group is acylated that is optionally isotopically labelled, for example, isotopically labelled carbonyl oxygen (e.g., 18 0) and/or isotopically labelled carbonyl carbon (e.g., 13 C or 14 C), etc.
- AA 3 is lysine having an isopropyl group attached to the side chain amino group.
- the isopropyl group is optionally isotopically labelled, e.g., with a plurality of deuterium and/or tritium atoms.
- a is 0.
- compounds have a disulfide bond to afford the ring system.
- AA 3 is lysine or a derivative thereof (e.g., the amino group of the side chain is alkylated, acylated, or substituted with an amine protecting group) that is optionally isotopically labelled.
- the side chain amino functional group is alkylated with an alkyl group optionally having one or more deuterium or tritium in lieu of hydrogen on the alkyl group.
- the side chain amino functional group is acylated that is optionally isotopically labelled, for example, isotopically labelled carbonyl oxygen (e.g., 18 0) and/or isotopically labelled carbonyl carbon (e.g., 13 C or 14 C), etc.
- AA 3 is lysine having an isopropyl group attached to the side chain amino group.
- the isopropyl group is optionally isotopically labelled, e.g., with a plurality of deuterium and/or tritium atoms.
- AA 2 and the sulfur atom to which it is attached to is cysteine, homocysteine, or penicillamine.
- AA 2 and the sulfur atom to which it is attached to is cysteine or homocysteine.
- AA 2 and the sulfur atom to which it is attached to is cysteine.
- AA 1 and the sulfur atom to which it is attached to is 3- mercaptopropionic acid (3 -MPA), cysteine, homocysteine, or penicillamine.
- AA 1 and the sulfur atom to which it is attached to is 3-MPA, cysteine or homocysteine.
- AA 1 and the sulfur atom to which it is attached to is cysteine.
- Ar 1 is phenyl.
- the -S-CH2- groups can be positioned at
- the -S-CH2- groups are positioned at 1,2-positions, i.e., the phenyl group is 1,2-disubstituted.
- Ar 1 is phenyl having one, two, three, or four, typically one, two, or three, often one or two, and most often one substituent(s).
- substituents suitable for Ar 1 include, but are not limited to, halides (e.g., F, Cl, I, or Br), C1-C10 alkyl (e.g., methyl, ethyl, t-butyl, isopropyl, etc.), C1-C10 haloalkyl (e.g., -CF 3 etc.), nitro, nitroso, -COnR (where n is 1 or 2 and R is hydrogen or alkyl), cyano, -OR (where R is H, alkyl, carbonyl, etc.), as well as other electron donating or electron withdrawing groups known to one skilled in the art.
- halides e.g., F, Cl, I, or Br
- C1-C10 alkyl e.g., methyl, ethyl, t-butyl, isopropyl, etc.
- C1-C10 haloalkyl e.g., -CF 3 etc.
- linker L 2 comprises a functional group that is capable of releasing Y 2 -Z in vivo. In this manner, the moiety Y 2 -Z is released in vivo thereby exerting its therapeutic activity.
- Suitable functional groups that is capable of releasing Y 2 -Z depends on the nature of the function group on moiety Y 2 that is linked to the linker L 2 . For example, when the function group on Z is a hydroxyl group (i.e., Y 2 is -OH) or an amino group (Y 2 is -MB), the functional group on L 2 can be a carboxylate such that an ester bond or an amide bond, respectively, is formed between the medically useful compound and linker L 2 .
- the corresponding functional group on L 2 can be a hydroxyl group or an amino group to form an ester bond or an amide bond, respectively.
- suitable functional groups on L 2 that is capable releasing the medically useful compound in vivo are well known to one skilled in the art including a disulfide bond linkage, an ester linkage, a thiol-maleimide linkage, and the like.
- the medically useful compound is a therapeutic agent.
- Suitable therapeutic agents include those that are known to one skilled in the art for treatment of cancer, autoimmune disease (e.g., rheumatoid arthritis), viral infection (e.g., HIV infection), etc.
- Exemplary therapeutic agents that are useful in compounds of the invention include, but are not limited to, Altretamine; Asparaginase; Bleomycin; Busulfan; Carboplatin; Carmustine; Chlorambucil; Cisplatin; Cladribine; Cyclophosphamide; Cytarabine; dacarbazine; Diethylstilbestrol; Eribulin, Ethinyl; estradiol; Etoposide; Mitomycin; Mitotane; Mitoxantrone; Paclitaxel; Pentastatin; Pipobroman; Plicamycin; Prednisone; Procarbazine; Streptozocin; Tamoxifen; Teniposide; Vinblastine; Vincristine, daunorubicin, doxorubicin, docetaxel, irinotecan, monomethyl auristatin E, mertansine, SN-38, tesirine, tubulysin, vinca alkaloids, and an
- L 2 can be any biocompatible bifunctional linker such as polyethylene glycol
- PEG polyamino acid
- L 2 is a polymer (e.g., PEG, PAA)
- the total number of monomers within the chain is from about 2 (i.e., a monomer) to about 20, typically from about 2 to about 15, often from about 3 to about 10, and most often from about 4 to about 6.
- medically useful compound is a diagnostic or imaging agent, such as a radioactive agent, fluorescent agent, etc.
- imaging agents are well known to one skilled in the art.
- contrast agents for magnetic resonance imaging agents, ultrasound contrast agents, and radio contrast agents See, for example, en.wikipedia.org/wiki/ Contrast_agent.
- Some specific examples of compounds of the invention include, but are not limited to, Compound of Formula A, Compound of Formula B, Compound of Formula C, Compound of Formula D, Compound of Formula E, Compound of Formula F, Compound of Formula G, Compound of Formula H, Compound of Formula I, Compound of Formula J, Compound of Formula K, Compound of Formula L, Compound of Formula M, Compound of Formula N, Compound of Formula O, and Compound of Formula P, each of which can also be labelled with deuterium (e.g., Compound of Formulas A-D12, B-D12, C-D12, etc.) or tritium (e.g., Compound of Formulas A-T12, B-T12, C-T12, ..., P-T12). Synthesis of these compounds are provided in the Examples section.
- deuterium e.g., Compound of Formulas A-D12, B-D12, C-D12, etc.
- tritium e.g., Compound of Formulas A
- compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carrier can include a diluent, an excipient, a flavoring agent, an adjuvant, a binder, a stabilizer, coloring agent, or a combination thereof.
- pharmaceutically acceptable carrier refers to any excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use.
- the present invention includes pharmaceutical compositions comprising at least one compound of the invention, or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
- the compounds of the invention are administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
- Suitable dosage ranges are typically 1-500 mg daily, typically 1-100 mg daily, and often 1-30 mg daily, depending on numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved.
- One of ordinary skill in the art of treating such diseases is typically able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of the invention.
- compounds of the invention are administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
- Typical manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
- a compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, can be placed into the form of pharmaceutical compositions and unit dosages.
- the pharmaceutical compositions and unit dosage forms can be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms can contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- compositions can be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
- Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
- the compounds of the invention can be formulated in a wide variety of oral administration dosage forms.
- the pharmaceutical compositions and dosage forms can comprise a compound or compounds of the invention or pharmaceutically acceptable salts thereof as the active component.
- the pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component.
- the active component In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound.
- Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term “preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be as solid forms suitable for oral administration.
- liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
- Emulsions can be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
- Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents.
- Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
- Solid form preparations include solutions, suspensions, and emulsions, and can contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the compounds of the invention can also be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and can be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi dose containers with an added preservative.
- parenteral administration e.g., by injection, for example bolus injection or continuous infusion
- the compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
- oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and can contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
- the active ingredient can be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
- the compounds of the invention can be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch.
- Ointments and creams can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions can be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
- Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- the compounds of the invention can be formulated for administration as suppositories.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
- the compounds of the invention can also be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- the compounds of the invention can be formulated for nasal administration.
- the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
- the formulations can be provided in a single or multidose form. In the latter case of a dropper or pipette, this can be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this can be achieved for example by means of a metering atomizing spray pump.
- the compounds of the invention can be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
- the compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size can be obtained by means known in the art, for example by micronization.
- the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, di chi orodifluorom ethane, tri chi orofluorom ethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas.
- CFC chlorofluorocarbon
- the aerosol can conveniently also contain a surfactant such as lecithin.
- the dose of drug can be controlled by a metered valve.
- the active ingredients can be provided in a form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
- the powder carrier typically forms a gel in the nasal cavity.
- the powder composition can be presented in unit dose form, for example, in capsules or cartridges of e.g., gelatine or blister packs from which the powder can be administered by means of an inhaler.
- formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
- the compounds of the invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary or desired and when patient compliance with a treatment regimen is crucial.
- Compounds in transdermal delivery systems are frequently attached to a skin-adhesive solid support.
- the compound of interest can also be combined with a penetration enhancer, e.g., Azone (l-dodecylazacycloheptan-2-one).
- Sustained release delivery systems can be inserted subcutaneously into the subdermal layer by surgery or injection.
- the subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
- the pharmaceutical preparations are typically in unit dosage forms.
- the preparation is often subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- compositions which include therapeutically effective mounts of compounds of Formula I or pharmaceutically acceptable salts thereof or a prodrug thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
- the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or simultaneously.
- the compounds of Formula I and pharmaceutically acceptable salts thereof are as described above.
- the carrier(s), diluent(s), or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- a process for the preparation of a pharmaceutical formulation including admixing a compound of Formula I, or a pharmaceutically acceptable salt thereof or a prodrug thereof, with one or more pharmaceutically acceptable carriers, diluents, or excipients.
- compositions of this disclosure comprise a combination of a compound of the present disclosure and one or more additional therapeutic or prophylactic agent
- both the compound and the additional agent are usually present at dosage levels of between about 10 to 150%, and more typically between about 10 and 80% of the dosage normally administered in a monotherapy regimen.
- Still another aspect of the invention provides a method for imaging cancer cells in a patient comprising administering to a patient an imaging effective amount of a high affinity CXCR4 selective binding ligand peptide conjugate of Formula I, the medically useful compound is an imaging agent, and imaging cancer cells in said patient using an imaging apparatus.
- the imaging apparatus used depends on the nature of imaging agent of compound of Formula I. For example, if the imaging agent is a positron-emitting radioisotope, then the imaging apparatus used is a PET scan, and when the medically useful compound is a contrasting agent, then the imaging apparatus can be a computed topography apparatus or an MRI apparatus. When the medically useful compound is a radioactive isotope, the imaging apparatus can be an x-ray machine or other similar device.
- One particular aspect of the invention provides a method for treating cancer in a patient.
- the method comprises administering a therapeutically effective amount of a compound of Formula I (where the medically useful compound is a cancer drug) or a pharmaceutical composition comprising a compound of Formula I (where the medically useful compound is a cancer drug) to a cancer patient.
- Another particular aspect of the invention provides a diagnostic or an imaging kit comprising a high affinity CXCR4 selective binding ligand peptide conjugate (PC) of Formula I, where the medically useful compound is a diagnostic agent or an imaging agent, respectively.
- PC selective binding ligand peptide conjugate
- Still another particular aspect of the invention provides a method for treating a patient suffering from rheumatoid arthritis, pulmonary fibrosis, HIV infection, or a cancer.
- the method includes administering a therapeutically effective amount of a compound of Formula I to a patient in need of treatment thereof.
- the medically useful compound of compound of Formula I is a therapeutic agent that can be used to treat the particular clinical condition to be treated.
- BOP (benzotriazol-l-yloxy)-tris(dimethylamino) phosphonium hexafluorophosphate
- Bz benzoyl
- Bzl benzyl
- Dab 1,4-diaminobutyric acid
- Dap 1,3-diaminopropionic acid
- DCC dicyclohexyl-carbodiimide
- DCM dichloromethane
- DIC diisopropyl carbodiimide
- DIEA diisopropyl-ethylamine
- DMAP 4-(N, A-di methyl ami no)pyri di ne
- DMF A' A -di methyl formamide
- DMSO dimethyl-sulfoxide
- EDT 1,2-ethane-dithiol
- Et ethyl
- Fmoc 9-fluor- enylmethoxy carbonyl
- HATU N-[(dimethyla
- MS Mass Spectroscopy
- Peptides were synthesized using solid phase peptide synthesis chemistry known in the art.
- the cyclic structure of those peptides was established, for a disulfide, by using air oxidation, or iodine oxidation in the presence of acidic acid, or for a bisthioether ring, by nucleophilic substitution using a bis(halomethyl) aryl compound, typically using 1.3 equivalents of a bis(bromom ethyl) aryl compound, in the presence of a base, such as 15 mM ammonium bicarbonate solution.
- a base such as 15 mM ammonium bicarbonate solution.
- Strong anion exchange resin (chloride form, substitution 3 mmole/g, water content 50%, using 2 grams of resin per gram of peptide) was first washed three times with milli Q water, then three times with 1 N NaOH solution three times, 5 min/time, and then five times with milli Q water, 5 min/time. The resin was further washed with 75% ethanol water until the pH reaches about 7.4. This resin was treated with 10% acetic acid solution three times, five minutes each time. The resin was then washed with 1% acetic acid solution three times, five minutes each time. The resin was ready for the salt conversion of the purified peptide.
- the purified, lyophilized peptide was dissolved in 1% acetic acid solution and added to the prepared resin described above. The mixture was agitated or magnetically stirred at room temperature for 1 h. The supernatant was separated. The resin was washed three times with 1% acetic acid solution. The supernatant and the washing solution were combined, filtered through a 0.22 pm membrane and lyophilized, to afford a peptide in acetate salt.
- Fmoc protection was removed again using 250 mL of 20% piperidine in DMF for 20 min.
- N-terminal acetylation was carried out with 160 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room temperature.
- the resin was then washed with 250 mL of DMF three time and then with 250 mL of DCM three times, then dried under vacuum to afford 81 grams of peptide resin containing the assembled target linear peptide.
- the dried resin was divided into several portions and one portion (20 grams) is used in the following operation.
- the crude peptide precipitates were washed three times with ethyl ether.
- the crude peptide was purified to a purity >90% on preparative HPLC, and lyophilized (MW MS: observed 1719.55; calculated: 1720.18).
- Fmoc protection was removed again using 25 mL of 20% piperidine in DMF for 20 min.
- N-terminal acetylation was carried out with 16 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room temperature.
- the peptide resin was then washed with 25 mL of DMF three time and followed by 25 mL of DCM three times, then the peptide resin dried under vacuum to afford 2.8 grams of peptide resin containing the assembled target linear peptide.
- Cys(Trt)-Lys(iPr, Boc)-PEG6 (SEQ ID NO: 11) was assembled by standard Fmoc chemistry using 2-chlorotrityl chloride resin. Briefly, 4.0 grams of the resin was swollen in DCM for 2 h, washed four times with DMF and then once with DCM. The loading of the first residue Fmoc- PEG6 was carried out in DCM using four equivalents of amino acid activated with five equivalents of DIEA. The coupling at room temperature for 1.5 h was followed by capping of the unreacted substitution sites with methanol/DIEA (1:1, v/v, 24 mL) for 30 min.
- the crude linear peptide cleavage and side chain protections were carried out using 10 mL of a cleavage cocktail of TFA/EDT/TIS/FLO/thioanisol e/phenol per gram of crude peptide resin (per 100 mL of solution contains 81.5 mL TFA, 2.5 mL EDT, 1.0 mL TIS, 5.0 mL FLO, 5.0 mL thioanisole, and 5.0 grams phenol) for 70 min at room temperature. Then to the cleavage mixture was added eight volumes of methyl t-butyl ether. The crude peptide precipitates were separated by centrifugation at 3000 rpm for 3 min. The crude peptide precipitates were washed three times with methyl t-butyl ether. The crude peptide was then dissolved in an aqueous acetonitrile and lyophilized.
- the crude lyophilized product was used directly in the cyclization reaction.
- the lyophilized crude peptide was dissolved in 20% acetic acid at 0.5 mg/mL. Under stirring, add 0.03% mole/L iodine solution until the peptide solution turned light yellow. The solution was protected from visible light during the cyclization. Cyclization was completed within 0.5 h as monitored by mass spectroscopy.
- the cyclized final product was purified using a reverse-phased preparative column Daisogel (50x250mm, 8pm) with mobile phases - A: 0.1% TFA water; B:
- Cys(Trt)- Lys(iPr,Boc)-PEG6-Lys(Boc) (SEQ ID NO: 13) was assembled manually by standard Fmoc chemistry using Rink AM resin. Briefly, 3.6 grams of Rink AM resin was swollen in DCM for 14 h and then washed four times with DMF. Removal of Fmoc was carried out in 20% piperidine in DMF for 20 min at room temperature and washed several times with DMF. Ninhydrin test was negative. Stepwise chain assembly started from the C-terminal end of the linear peptide and was accomplished in nine major steps.
- step 1 three equivalents of protected amino acid Fmoc-Lys(Boc) were activated with DIC/HOBt in DMF, and coupled to the Fmoc-removed Rink AM resin above for 2 h at room temperature followed by Fmoc removal using 20% piperidine in DMF for 20 min.
- step 2 three equivalents of Fmoc-PEG6 acid were activated with DCC/HOBt in DMF and coupled to the deprotected resin from step 1.
- the finished peptide was deprotected and cleaved from the resin using 10 mL/gram of resin of a cleavage cocktail of TFA/EDT/TIS/FLO/thioanisole/ phenol (per 100 mL of solution contains 81.5 mL TFA, 2.5 mL EDT, 1.0 mL TIS, 5.0 mL FLO, 5.0 mL thioanisole, and 5.0 grams phenol) for 70 min at room temperature. To the cleavage mixture was added eight volumes of methyl t-butyl ether. The crude peptide precipitates were separated by centrifugation at 3000 rpm for 3 min. The crude peptide precipitates were washed three times with methyl t- butyl ether. The crude peptide was then dissolved in aqueous acetonitrile and lyophilized.
- the crude lyophilized product was used directly in the cyclization reaction.
- the lyophilized crude peptide was dissolved in water containing 20% acetic acid at 0.5 mg/mL (500 mg of crude peptide in one liter). Under stirring, 0.03% mole/L iodine solution was added to the peptide solution until the solution became pale yellow. Cyclization was complete within 0.5 h in dark as monitored by mass spectroscopy.
- the cyclized final product was purified using a reverse-phased preparative column Daisogel (50x250mm, 8pm); mobile phases - Solvent A:
- Cys(Mmt)- Lys(iPr,Boc)-PEG6-Cys(Trt) (SEQ ID NO: 15) was assembled by standard Fmoc chemistry using Sieber amide AM resin (Xi’an LanXiao Chemical Limited, Xi’an, China). Briefly, 4 g of Sieber amide AM resin was swollen in 30 mL of DCM for 2 h and then washed four times with DMF. Removal of Fmoc was carried out in 25 mL of 20% piperidine in DMF for 20 min at room temperature and washed several times with DMF. Ninhydrin test was negative.
- Stepwise chain assembly started with Fmoc-Cys(Trt)-OH from the C-terminal end of the linear peptide.
- Three equivalents of protected amino acid Fmoc-Cys(Trt)-OH were activated with DIC/HOBt in 8 mL of DMF, and coupled to the Fmoc-removed Sieber amide AM resin prepared above for 2 h at room temperature. Ninhydrin test was negative. Capping of the non-reacted amino group was performed for 30 min with 16 mL of a mixture of acetic anhydride/DIEA/DCM at a volume ratio of 1 : 1 :4. This was followed by Fmoc removal using 25 mL of 20% piperidine in DMF for 20 min.
- Fmoc protection was removed again using 25 mL of 20% piperidine in DMF for 20 min.
- N-terminal acetylation was carried out with 16 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room temperature.
- the resin was then washed with 25 mL of DMF three time and then with 25 mL of DCM three times, then dried under vacuum to afford 8 grams of peptide resin containing the assembled target linear peptide. The dried resin was used in the following operation.
- the cleavage solutions containing the partially deprotected linear peptide were combined and concentrated under vacuum using a rotary evaporator. The residues (crude peptide) were then lyophilized to afford about 1 gram of partially deprotected crude linear peptide.
- the crude lyophilized product was used directly in the cyclization reaction.
- the lyophilized crude peptide was dissolved in water containing 20% acetic acid at 0.5 mg/mL (500 mg of crude peptide in one liter). Under stirring, 0.03% mole/L iodine solution was added to the peptide solution until the solution became pale yellow. Cyclization was complete within 0.5 h in dark as monitored by mass spectroscopy.
- the cyclization reaction was allowed to proceed for 1 h at room temperature. The reaction mixture was then divided into several equal portions and lyophilized.
- CXCR4 peptide Compound C are dissolved in 100 mL of MeCN/water (1:1, v/v). The solution is adjusted to pH 7-7.5 using 0.5M of ammonium bicarbonate. The conjugation reaction is monitored by MS and the reaction completed in about half an hour. The final product is purified using a reverse-phased preparative column Daisogel (50x250mm, 8pm); mobile phases - Solvent A: 0.1% TFA water; Solvent B: 0.1% TFA acetonitrile. Fractions containing the target product Compound F are combined and lyophilized (a TFA salt). Salt exchange as described above affords a peptide in acetate salt.
- deuterium labelled (B-D12) and tritium labelled (B-T12) compounds provide synthesis of corresponding deuterium labelled (“-D12”) and tritium labelled (i.e., “-T12”) compounds A-P, i.e., compounds A-D12, A-T12, B-D12, B-T12, C-D12, C-T12, P-D12, and P-T12
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a selective CXCR4 binding peptide conjugate ("PC"), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate ("PC") is of the formula: (SEQ ID NO:1) or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders. Compositions, kits and methods are also disclosed herein for such uses.
Description
ISOTOPICALLY LABELLED SELECTIVE CXCR4 BINDING PEPTIDE CONJUGATE AND METHODS FOR MAKING AND USING THE SAME
FIELD OF THE INVENTION
[0001] The present invention relates to an isotopically labelled selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the isotopically labelled selective CXCR4 binding peptide conjugate of the invention is isoptocially labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium,
13C, 14C, 180, or a combination thereof and comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound.
BACKGROUND OF THE INVENTION
[0002] CXCL12 (also called stromal cell-derived factor-1 or SDF-1) and CXCR4, a chemokine and chemokine receptor pair play important roles in hematopoiesis, multiple stages of tumorigenesis, and embryonic development. For example, activation of CXCR4 by CXCL12 has shown to direct leukocyte chemotaxis in the immune system in response to inflammation and progenitor cell migration during embryologic development. Activation of CXCR4 by CXCL12 has also been shown to mediate signaling pathway that is involved in breast cancer metastasis and memory T cell migration.
[0003] CXCR4, a G-protein-coupled receptor also known as fusion or CD 184 (cluster of differentiation 184), is constitutively- or over-expressed in a wide variety of human cancers, promoting local tumor cell proliferation, survival and angiogenesis. It has also been reported that CXCR4 is a co-receptor for HIV entry and infection of host cells and has been evaluated as a potential HIV therapy.
[0004] Reports have confirmed that CXCR4 is overexpressed in numerous human cancers. CXCR4 antagonism has been shown to disrupt tumor-stromal interactions, sensitize cancer cells to cytotoxic drugs, and reduce tumor growth and metastatic burden. Hence, CXCR4 is a target not only for potential therapeutic intervention of cancer treatment, but also for noninvasive monitoring of disease progression, therapeutic guidance, and other diagnostic
purposes. Some have even suggested that binding and interacting with CXCR4 as a potential way of targeted drug delivery.
[0005] Thus, it is believed that compounds having a moiety that can selectively bind
CXCR4 (i.e., CXCR4 selective binding conjugate) can have a wide variety uses including, but not limited to, treating a wide array of clinical conditions associated with activation or over expression of CXCR4, diagnosing a patient, and medical imaging. Moreover, by labelling a moiety that can selectively bind to CXCR4, one can study the various mode of drug delivery, drug interaction, diagnosis, in vivo imaging of cells affected by over-expression of CXCR4, etc. It would be more useful, if such a labelled compound does not significantly alter the interaction with CXCR4.
[0006] Accordingly, there is a need for conjugates that can selectively bind to CXCR4 having a medically useful compound. In addition, there is a need for a labelled conjugate that does not significantly alter the physical properties, such as a binding constant, drug activity, its three-dimensional structure, etc.
SUMMARY OF THE INVENTION
[0007] The present invention provides an isotopically labelled selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention is isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13C, 14C, 180, and/or a combination thereof deuterium, tritium, 13C, 14C, 180, or a combination thereof, and comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In some embodiment, the peptidyl portion of the compounds of the invention is isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13C, 14C, 180, or a combination thereof. In this manner, one can readily trace, image, or study the compounds in vivo. The peptide or peptidyl portion is linked to the medically useful compound via a polymeric linker. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery, imaging a patient, studying the medically useful compound in vivo (e.g., interaction with CXCR4, etc.), diagnosing a patient for a disease or a clinical condition associated with
overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders. Compositions, kits and methods are also disclosed herein for such uses.
[0008] In one particular aspect of the invention provides an isotopically labelled selective
CXCR4 binding peptide conjugate (“PC”) of the formula:
I or a pharmaceutically acceptable salt thereof, wherein: a is 0 or 1; b is an integer from 1 to 4;
AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, optionally substituted homocysteine, or optionally substituted penicillamine;
AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine;
Ar1 is an optionally substituted aryl;
X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); each of AA3 is independently Gly, Phe, 2Nal, INal, Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr); and wherein at least one of AA1, X1, AA2, or AA3 comprises a moiety of the formula:
-L!-Q, wherein
L1 is a polymeric linker having a functional group for linking Q, wherein L1 comprises from about 2 to about 20 monomers or copolymers;
Q is absent, AA4, or a moiety of the formula: -[AA4-Y1-L2]C-Y2-Z, wherein c is 0 or 1;
AA4 is an amino acid or a derivative thereof;
Y1 is a side-chain function group of amino acid AA4;
L2 is a non-polymeric linker;
Z a medically useful compound; and
Y2 is a functional group of said medically useful compound or a functional group of L2; and wherein one or more of AA1, AA2, X1, AA3, and AA4 are isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13C, 14C, 180, or a combination thereof.
[0009] The medically useful compounds that can be used in the invention include, but are not limited to, compounds that can be used in diagnosis, treatment, or assaying various clinical conditions. Exemplary medically useful compounds include, but are not limited, imaging agents, contrast agents, and therapeutic agents (e.g., drugs).
[0010] In some embodiments, the selective CXCR4 binding peptide conjugate of the invention is of the formula:
IA wherein a, b, AA1, X1, AA2, AA3, L1, Q, and Ar1 are those defined herein. Throughout this disclosure, the terms “those defined herein” and “those defined above” when referring to a variable incorporates by reference the broad definition of the variable as well as any narrower definitions including preferred, more preferred and most preferred definitions, if any.
[0011] In some embodiment, Q is absent from compounds of formulas disclosed herein.
In this manner, at least one of AA1, X1, AA2, or AA3 comprises a moiety of the formula -L1.
Such a compound can be used as a starting material for attaching or linking AA4,
-AA4-Y'-L2, or a moiety of the formula: -[AA4-Y1-L2]C-Y2-Z.
[0012] Still in other embodiments, Q is AA4. Such a compound can be used for attaching or linking a moiety of the formula -Y'-L2-Y2-Z.
[0013] Yet in other embodiments, Q is a moiety of the formula: -[AA4-Y1-L2]C-Y2-Z.
Thus, the invention provides both starting materials for attaching a medically useful compound as well as selective CXCR4 binding peptide conjugates that include at least one medically useful compound.
[0014] In other embodiments, a is 0. Still in other embodiments, a is 1.
[0015] Yet still in other embodiments, at least one of X1 and AA3 is isotopically labelled.
In other embodiments, both X1 and AA3 are isotopically labelled. Exemplary isotopic labels include, but are not limited to, deuterium, tritium, 13C, 14C, 180, and a combination thereof. In one particular embodiment, isotopic label comprises deuterium or tritium. Typically, the isotopically labelled X1 and/or AA3 comprises deuterium, tritium, 13C, 14C, 180, or a combination thereof. In one particular embodiment, at least one of X1 and AA3 is isotopic labelled with deuterium or tritium. In one specific embodiment, X1 and AA3 are isotopically labelled Lys(iPr). More specifically, in one embodiment, X1 and AA3 are both Lys(deuterated iPr).
[0016] Still yet in other embodiments, the medically useful compound is a therapeutic agent. In some embodiments, the therapeutic agent is an anticancer agent. Exemplary anticancer agents that can be used in the invention include, but are not limited to, paclitaxel, Altretamine, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Diethylstilbestrol, Eribulin, Ethinyl, estradiol, Etoposide, Mitomycin, Mitotane, Mitoxantrone, Pentastatin, Pipobroman, Plicamycin, Prednisone, Procarbazine, Streptozocin, Tamoxifen, Teniposide, Vinblastine, and Vincristine. In general, any anticancer agent that has a functional group suitable for linkage can be used. Such anticancer agents will be readily apparent to one skilled in the art having read the present disclosure.
[0017] In other embodiments, the isotopically labelled selective CXCR4 binding peptide conjugate of the invention of the formula:
IB wherein a, b, AA1, X1, AA2, AA3, AA4, Y1, Y2, L2, Z, and Ar1 are those defined herein; and Lla is a polymeric linker comprising from about 2 to about 20 monomers or copolymers.
[0018] Yet in some embodiments, L2 is a non-polymeric linker of the formula:
-CH2-C(=0)-NH-CH2-, -CH2-NH-C(=0)-CH2-, -(CH2)„-C(=0)-NH-CH2- -(CH2)n-NH-C(=0)-CH2-, or -(CH2)n-, wherein n = is an integer from 1 to 6.
[0019] Still in other embodiments, AA1 along with the sulfur atom that is attached thereto is optionally substituted cysteine or optionally substituted homocysteine. For example, the a- amino group of AA1 can be substituted with an acyl group (e.g., acetyl group, etc.), alkyl group (e.g., methyl, dimethyl, ethyl, dimethyl, propyl, dipropyl, iso-propyl, di(iso-propyl), etc.), haloalkyl (e.g., trifluoromethyl, ditrifluoromethyl, etc.). Other suitable substituents for AA1 will be readily apparent to one skilled in the art having read the present disclosure.
[0020] Similar to AA1, AA2 along with the sulfur atom that is attached thereto can also be an optionally substituted cysteine or optionally substituted homocysteine.
[0021] In one particular embodiment, X1 and/or at least one of AA3 is Lys(iPr) or
Lys(deuterated-iPr). When deuterated (e.g., “deuterated-iPr”), iso-propyl group (“iPr”) can have one or more hydrogen atom that is replaced with a deuterium. In some embodiments, at least 2, typically at least 3, often at least 4, more often at least 5 and most often at least 6 hydrogen atoms of iPr are replaced with deuterium atoms. Throughout this disclosure, a short hand notation for amino acids AA(X) refers to amino acid AA that is substituted with “X” on the side chain functional group. For example, Lys(iPr) refers to lysine that is substituted with iso-propyl group on the amine functional group of lysine’s side chain.
[0022] Yet other embodiments of the invention, Ar1 is phenyl. In one particular embodiment, Ar1 is of the formula:
[0023] Still in another particular embodiment of the invention, b is 1. Within this embodiment, in some instances, b is 1 and AA3 is Lys(iPr) or Lys(deuterated-iPr).
[0024] In another embodiment of the invention, L1 is a polymeric linker of the formula:
-NH-(CH2)2-[0-CH2-CH2-]n-0-(CH2)2-C(=0)-, wherein n is an integer from 2 to 20, typically, from 2 to 15, often from 2 to 10, still more often from 2 to 8, yet more often from 2 to 6, and most often 3 to 6. In some instances, -NH- is attached to the carbonyl carbon of amino acid AA3. Still in other instances, -C(=0)- is attached to a-amino functional group of amino acid AA4.
[0025] In one particular embodiment, AA4 is cysteine, homocysteine, or penicillin amine.
[0026] Still in other embodiments, at least one of AA1, X1, AA2, or AA3 amino acid residue is a (D)-isomer.
[0027] Yet in other embodiments, a is 0.
[0028] In yet other embodiments, AA1 is homocysteine.
[0029] Exemplary selective CXCR4 binding peptide conjugates of the invention include, but are not limited to, Compound of Formula A, Compound of Formula B, Compound of Formula C, Compound of Formula D, Compound of Formula E, Compound of Formula F, Compound of Formula G, Compound of Formula H, Compound of Formula I, Compound of Formula J, Compound of Formula K, Compound of Formula L, Compound of Formula M, Compound of Formula N, Compound of Formula O, and Compound of Formula P, as well as the corresponding deuterium labelled compounds (i.e., -D12) and tritium labelled compounds (i.e., - T12).
[0030] Another aspect of the invention provides a method for treating a subject suffering from a cancer, said method comprising administering to the subject a therapeutically effective amount of a selective CXCR4 binding peptide conjugate disclosed herein, wherein said medically useful compound is an anticancer agent. Exemplary anticancer agents used methods of the invention include, but are not limited to, paclitaxel, Altretamine, Asparaginase,
Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Diethylstilbestrol, Eribulin, Ethinyl, estradiol, Etoposide, Mitomycin, Mitotane, Mitoxantrone, Pentastatin, Pipobroman, Plicamycin, Prednisone, Procarbazine, Streptozocin, Tamoxifen, Teniposide, Vinblastine, and Vincristine.
[0031] In some embodiments, methods of the invention provide treatment of cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, kidney cancer, brain cancer, blood cancer, leukemia, prostate cancer, ovarian cancer, and bladder cancer.
DETAILED DESCRIPTION OF THE INVENTION
[0032] CXCR4 plays an important role in immune and inflammatory responses in various diseases and disorders, including cancer, viral infections, as well as autoimmune pathologies such as rheumatoid arthritis. The present invention is based at least in part on reducing or preventing overexpression or activation of CXCR4 to treat, diagnose or image a clinical condition associated with CXCR4 overexpression and/or activation. As used herein, the term “overexpression and/or activation” refers to expression of a gene above its normal (i.e., control) or baseline level and/or activation of CXCR4 above its normal, control or baseline level, respectively.
[0033] The terms “normal,” “baseline level” and “control level” are used interchangeably herein and refer to expression and/or activity level of CXCR4 in subject(s) that do not have a disease or a clinical condition associated with overexpression and/or activation of CXCR4, such as those disclosed herein. In some embodiments, the baseline level can be a normal level, meaning the level in a sample from a normal subject that do not have a clinical condition associated with overexpression and/or activation (or activity) of CXCR4. This allows a determination based on the baseline level of CXCR4 expression or its biological activity, i.e., whether a sample to be tested or evaluated for disease or a clinical condition has a measurable increase, decrease, or substantially no change in CXCR4 expression or activation as compared to the baseline level.
[0034] It should be appreciated that the overexpression and/or activation of CXCR4 can also be determined by comparing the sample result with a positive control. The term “positive control” as used herein refers to a level of CXCR4 expression and/or activation (or activity) established in a sample from a subject or from a population of individuals, where the sample was believed, based on data from that sample, to have a disease or a clinical condition associated with overexpression and/or activation of CXCR4 (e.g., cancer, autoimmune disease such as rheumatoid arthritis and viral infection, such as HIV infection).
[0035] In other embodiments, the baseline level can be established from a previous sample from the subject being tested, so that the disease progression or regression of the subject can be monitored over time and/or the efficacy of treatment can be evaluated.
[0036] Some aspects of the invention provide compounds that have a high affinity toward
CXCR4 that is attached to a diagnostic agent, a therapeutic agent or an imaging agent, through a linker. Such compounds include a CXCR4 binding moiety and a medically active component (or simply “an active compound”). As used herein, the term “medically active compound” refers to a compound that is a therapeutically active, or can be used in diagnostic or imaging, or any other uses associated with treatment, diagnostic, imaging, analysis or other uses in clinical applications. The invention also provides methods for using the same, e.g., in targeted delivery of therapeutics to treat clinical conditions manifested by or associated with overexpression and/or activation of CXCR4, imaging (e.g., in vivo or in vitro ) cells associated with CRCR4, identifying cells overexpressing or cells having activated CXCR4, etc. As used herein, the term “high affinity” or “selective” means the compound or the moiety that binds to CXCR4 has a binding constant (Kb) of about 10 nM or less, typically about 3 nM or less, and often 1 nM or less. Alternatively, the term “high affinity” or “selective” means the compound or the moiety that binds to CXCR4 has 50% binding inhibition concentration (IC50) of about 30 nM or less, typically about 10 nM or less and often about 3 nM or less. Methods for determining binding constant and IC50 are well known to one skilled in the art. See, for example, commonly assigned U.S. provisional patent application numbers 62/384,132, filed September 6, 2016, and 62/505,064, filed May 11, 2017, and commonly assigned PCT patent application no. PCT/US17/50106, filed September 5, 2017, all of which are incorporated herein by reference in their entirety. In particular, the values Kb and IC50 are determined using the CXCR4/125I-SDF-la binding assay described in the above referenced provisional patent applications.
[0037] When referring to a numerical value, the terms “about” and “approximately” are used interchangeably herein and refer to being within an acceptable error range for the particular value as determined by one of ordinary skill in the art. Such a value determination will depend at least in part on how the value is measured or determined, e.g., the limitations of the measurement system, i.e., the degree of precision required for a particular purpose. For example, the term “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, the term “about” when referring to a numerical value can mean ± 20%, typically ± 10%, often ± 5% and more often ± 1 % of the numerical value. In general, however, where particular values are described in the application and claims, unless otherwise stated, the term
“about” means within an acceptable error range for the particular value, typically within one standard deviation.
[0038] In one particular aspect of the invention, a high affinity or selective CXCR4 binding peptide conjugate (“PC”) is of the Formula:
I or a pharmaceutically acceptable salt thereof, wherein: a is 0 or 1; b is an integer from 1 to 4;
AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine;
AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, optionally substituted homocysteine, or optionally substituted penicillamine;
AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine;
Ar1 is an optionally substituted aryl;
X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); each of AA3 is independently Gly, Phe, 2Nal, INal, Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr); and wherein at least one of AA1, X1, AA2, or AA3 comprises a moiety of the formula:
-L!-Q, wherein
L1 is a polymeric linker having a functional group for linking Q, wherein L1 comprises from about 2 to about 20 monomers or copolymers;
Q is absent, AA4, or a moiety of the formula: -[AA4-Y1-L2]C-Y2-Z, wherein c is 0 or 1;
AA4 is an amino acid or a derivative thereof;
Y1 is a side-chain function group of amino acid AA4;
L2 is a non-polymeric linker;
Z a medically useful compound; and
Y2 is a functional group of said medically useful compound or a functional group of L2; and wherein one or more of AA1, AA2, X1, AA3, and AA4 are isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13C, 14C, 180, or a combination thereof.
[0039] “Pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4- hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2 -hydroxy ethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-lcarboxylic acid, glucoheptonic acid, 3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N- methylglucamine, and the like.
[0040] It should be appreciated that the terms “optionally substituted” when referring to an amino acid, means the side chain functional group of the amino acid or the a-amino group of the amino acid may be substituted, for example, by an alkyl (e.g., Ci-Cio alkyl) or a functional group protecting group, etc. For example, for lysine or other amino acids having a side chain with a nitrogen heteroatom, optionally substituted or “derivative thereof’ includes those
substituted with an alkyl, a nitrogen protecting group (e.g., acyl containing moieties), and/or a haloalkyl (e.g., trifluoromethyl, etc.). For cysteine and other sulfur heteroatom containing amino acids (including homocysteine and penicillamine), the terms “optionally substituted” and “derivatives thereof’ can include those that are optionally substituted on the sulfur atom or the a- amine functional group, such as those with alkyl, thiol or amine protecting group, etc. Typically, when referring to AA1 and AA4, the term optionally substituted refers to substitution on the a- amine group. Exemplary substitutions on the a-amine group include, but are not limited to, alkyl group, and amine protecting group, as well as those other substituents known to one skilled in the art. “Protecting group” refers to a moiety that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis , 3rd edition, John Wiley & Sons, New York, 1999, and Harrison and Harrison et ah, Compendium of Synthetic Organic Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996), which are incorporated herein by reference in their entirety.
[0041] AA4 is an amino acid or a derivative thereof, where AA4 has a side-chain functional group Y1. This presence of the side chain functional group allows attaching linker L2 to the amino acid AA4. It should be appreciated that, while the functional group Y1 when attached to L1 has one less hydrogen atom attached thereto. For example, in lysine the side chain functional group is -ME, thus Y1 when it is not linked to L2 is -Mb and when it is linked to L2, Y1 is -NH-. Thus, it should be understood that the number of hydrogen atom attached to or is present on Y1 is omitted merely for brevity. Furthermore, the side-chain functional group of any amino acid can be readily changed by one skilled in the art. For example, the hydroxy side chain functional group of serine can be changed to an amine, carboxylic acid, or other functional groups by one skilled in the art using the known reaction procedures. In addition, amine side chain functional group (i.e., -Mb) of lysine can be changed to azide, -NH-N3, hydroxy, amide, phosphate, thiol, etc.
[0042] In one particular embodiment, X1 is isotopically labelled. Still in another embodiment, AA3 is isotopically labelled.
[0043] In some embodiments, X1 and/or AA3 are/is isotopically labelled. Isotopically labelled compound of Formula I can be used inter alia for imaging and/or diagnostic purposes.
Exemplary isotopically labelled X1 and/or AA3 include those comprising a positron-emitting radioisotope such 34C1, 45Ti, 51Mn, 61Cu, 63Zn, 68Ga, nC, 13N, 150, and 18F. When radioisotope is used, typically such radioisotopes are complexed to X1 and/or AA3 via a complexing or coordinating agent. Suitable complexing or coordinating moieties are well known to one skilled in the art. Other useful isotopic labels include, but are not limited to, deuterium (D), tritium (T), 13C, 14C, 180, or a combination thereof.
[0044] Another example of a useful imaging agent includes a radioactive metal isotope that is coordinated (i.e., chelated) to a chelating group. Particularly useful radioactive metal isotopes include technetium, rhenium, gallium, gadolinium, indium, copper and a combination thereof. Appropriate chelating groups for a particular radioactive metal isotope are well known to one skilled in the art. For example, ferrocene and its derivatives, ethylenediaminetetraacetic acid (“EDTA”), its derivatives, a peptidyl moiety Dap-Asp-Cys and its derivatives (see U.S. Pat. No. 7,128,893), and others known in the art.
[0045] Yet another example of a useful imaging agent includes a contrasting agent.
Contrasting agents are widely used, for example, in magnetic resonance imaging (MRI). Wide variety of contrasting agents are known to one skilled in the art including gadobenate, gadobutrol, gadodiamide, gadofosveset, gadopentetate, gadoterate, gadoteridol, gadoversetamide, gadoxetate, and iron oxide.
[0046] Still another example of a useful imaging agent includes a fluorescent dye, such as fluorenylmethyloxycarbonyl (FMOC) and its derivatives, an AlexaFluor dye, an Oregon Green dye, a fluoresceins, a BODIPY (boron-dipyrromethene) dye, a cyanine dye, a rhodamine dye, a Dy Light dye, and Texas Red.
[0047] In other embodiments, X1 and/or AA3 comprises (e.g., attached or linked to) a diagnostic agent, such as an imaging agent, an isotopic agent, or a radioactive agent. In one particular embodiment, X1 and/or AA3 is isotopically labelled. In some instances, X1 and/or AA3 is lysine that is substituted with isotopically labelled side-chain. As used herein, the term “side- chain” or “side chain” when referring to an amino acid is used to describe the “R” group in the following formula: H2N-CH(R)-C02H. Side chain for a given amino acid is well known to one skilled in the art, for example, the side chain or “R” for glycine is H, for serine it is a moiety of the formula -CFEOH, etc. In other instances, X1 and/or AA3 is lysine in which the side chain
functional group amine is substituted with an isotopically labelled alkyl group. As used herein, the term “isotopically labelled alkyl group” means either the carbon or the hydrogen atom(s) in the alkyl group is replaced with a corresponding isotope such as 13C and/or 14C for carbon atom(s), or deuterium or tritium for hydrogen atom(s). In some instances, the amine nitrogen of the lysine side chain functional group is isotopically labelled with 13N. Still in other embodiments, the carbonyl oxygen of the amino acid is isotopically labelled with 180. Yet in other embodiments, one or more carbon atoms in the amino acid X1 and/or AA3 is isotopically labelled with 13C or 14C. Still in other embodiments, a-amino functional group of amino acid X1 and/or AA3 is isotopically labelled with 14N. Yet still in other embodiments, a-amino functional group of amino acid X1 and/or AA3 can be substituted with isotopically labelled group, such as isotopically labelled carbonyl group (e.g., 180, 13C, 14C labelled carbonyl group) or isotopically labelled alkyl group (e.g., D, T, 13C, or 14C).
[0048] In one specific embodiment, X1 and/or AA3 is Lys(iPr) or D-Lys(iPr) where one or more, typically two or more, often three or more, more often four or more, still more often five or more and most often at least six hydrogen atoms on the iPr group is isotopically labelled (i.e., replaced with) with deuterium or tritium.
[0049] As can be seen in formula I, in one embodiment the peptidyl group is linked to a medically useful compound of the formula Z by using the functional group “Y2” that is present on the medically useful compound or alternatively that is present on linker L2. Such an attachment is well known and can be readily achieved by one skilled in the art. For example, when the functional group Y2 is part of the linker L2, medically useful compound Z is modified such that a leaving group or other suitable bond forming agent is present in Z, e.g., if Y2 is an amino group of L2, it can be used to displace a halide or other suitable leaving groups (e.g., mesylate, tosylate, etc.) or connect to a carbonyl group that is present in the medically useful compound Z to form an amine or amide linkage, respectively. Similarly, if Y2 is a hydroxyl group, it can be used to displace a halide or other leaving group or connect to a carbonyl group that is present in the medically useful compound to form an ether or an ester, respectively. In a similar manner, if the function group Y2 is present on the medically useful compound Z, then Y2 can be used to attach linker L2. For example, by linking a hydroxyl or an amino group that is present on the medically useful compound to a carbonyl group that is present on the non-
polymeric linker L2. In this manner, an ester or an amide bond can be formed, respectively, between the medically useful compound and linker L2. Other suitable functional groups for Y2 will be readily recognized by one skilled in the art having read to present disclosure.
[0050] Still in some embodiments, L2 is a non-polymeric linker of the formula selected from the group consisting of -CH2-C(=0)-, -NH-CH2-, -(CH2)n-C(=0)-NH-CH2-, -(CH2)n-NH-C(=0)-CH2-, or -(CH2)n-, where n is an integer from 1 to 6. In one particular embodiment, L2 is -CH2-C(=0)- and Y2 is O.
[0051] In formula I, amino acid AA4 is an amino acid having a side chain with a functional group -Y1. This allows attachment of linker L2 to the heteroatom Y1. Thus, suitable amino acids AA4 include, but are not limited to, serine, cysteine, lysine, arginine, aspartic acid, glutamine, glutamic acid, histidine, proline, threonine, tryptophan, tyrosine, and the like, as well as homologs or derivatives thereof, such as homocysteine, homoserine. In addition, AA4 can also be a non-proteinogenic amino acid, a synthetic amino acid, or an “unnatural amino acid”, i.e., an amino acid that does not occur naturally but are well known to one skilled in the art, such as ornithine, 1,4-diaminobutyric acid (Dab), 1,3-diaminopropionic acid (Dap), penicillamine, etc. In one particular embodiment, AA4 is cysteine, homocysteine, or penicillamine. In such instances, Y1 is sulfur (e.g., thiol). In another specific embodiment, AA4 is serine, in which instances Y1 is oxygen (e.g., a hydroxyl group).
[0052] Unless otherwise stated or context requires otherwise, amino acids disclosed herein can be either (D)- or (L)- stereo configuration. In fact, in some embodiments, one or more amino acids are (D)-configuration. In this manner, in vivo stability of compound of Formula I can be greatly enhanced or increased. Typically, unless stated otherwise amino acids of the invention are proteinogenic amino acids.
[0053] Still in other embodiments, L1 is a polymeric linker comprising from about 2 to about 20, typically from about 2 to about 15, often from about 2 to about 10, more often from about 2 to 8, and most often from about 5 to about 8 monomers or copolymers. Copolymer refers to a linker having two or more different monomeric units. For example, a copolymer can be a polymer that is formed between ethylene glycol propylene glycol units; between ethylene glycol and vinyl alcohol units; between ethylene glycol and vinyl acetate units; as well as other copolymers that are well known to one skilled in the art. It should be appreciated that the two
end units of L1 (e.g., one end that is attached to AA3 and the other end unit that is attached to AA4 are functionalized such that it can readily be linked to AA3 and AA4. For example, when L1 is a polyethylene glycol (“PEG”), one end of the PEG that is attached to AA3 can be functionalized as an amine so that it forms an amide bond with AA3. If on the other hand, if the end of the PEG that is attached to AA3 is maintained as a hydroxyl group, then it forms an ester bond with AA3. Similar, if the hydroxyl group of PEG that is attached to AA4 is oxidized to a carboxylic acid moiety, then it forms an amide group with the a-amino functional group of AA4. Or when the hydroxyl group of PEG that is attached to AA4 is replaced with a leaving group (e.g., tosylate, mesylate, halide, etc.), it can form an amino linkage with the a-amino functional group of AA4 by, e.g., a displacement reaction. In this manner, a wide variety of methods are available for linking L1 to AA3 and AA4. In one specific embodiment, L1 is a polyethylene glycol in which the end attached to AA3 is an amino group, thereby forming an amide bond with AA3. In another embodiment, L1 is a polyethylene glycol in which the end that is attached to AA4 is oxidized to a carboxylic acid or similar functional group, thereby forming an amide linkage with the a-amino functional group of amino acid AA4.
[0054] In some embodiments, a is 1. In one particular embodiment, AA3 is lysine or a derivative thereof (e.g., the amino group of the side chain is alkylated, acylated, or substituted with an amine protecting group) that is optionally isotopically labelled. In some embodiments, the side chain amino functional group is alkylated with an alkyl group optionally having one or more deuterium or tritium in lieu of hydrogen on the alkyl group. In some embodiments, the side chain amino functional group is acylated that is optionally isotopically labelled, for example, isotopically labelled carbonyl oxygen (e.g., 180) and/or isotopically labelled carbonyl carbon (e.g., 13C or 14C), etc. In one particular embodiment, AA3 is lysine having an isopropyl group attached to the side chain amino group. In one specific embodiment, the isopropyl group is optionally isotopically labelled, e.g., with a plurality of deuterium and/or tritium atoms.
[0055] In some embodiments, a is 0. In this embodiment, compounds have a disulfide bond to afford the ring system.
[0056] Still in other embodiments, AA3 is lysine or a derivative thereof (e.g., the amino group of the side chain is alkylated, acylated, or substituted with an amine protecting group) that is optionally isotopically labelled. In some embodiments, the side chain amino functional group
is alkylated with an alkyl group optionally having one or more deuterium or tritium in lieu of hydrogen on the alkyl group. In some embodiments, the side chain amino functional group is acylated that is optionally isotopically labelled, for example, isotopically labelled carbonyl oxygen (e.g., 180) and/or isotopically labelled carbonyl carbon (e.g., 13C or 14C), etc. In one particular embodiment, AA3 is lysine having an isopropyl group attached to the side chain amino group. In one specific embodiment, the isopropyl group is optionally isotopically labelled, e.g., with a plurality of deuterium and/or tritium atoms.
[0057] Yet in other embodiments, AA2 and the sulfur atom to which it is attached to is cysteine, homocysteine, or penicillamine. Typically, AA2 and the sulfur atom to which it is attached to is cysteine or homocysteine. In one specific embodiment, AA2 and the sulfur atom to which it is attached to is cysteine.
[0058] Still in other embodiments, AA1 and the sulfur atom to which it is attached to is 3- mercaptopropionic acid (3 -MPA), cysteine, homocysteine, or penicillamine. Typically, AA1 and the sulfur atom to which it is attached to is 3-MPA, cysteine or homocysteine. In one specific embodiment, AA1 and the sulfur atom to which it is attached to is cysteine.
[0059] In other embodiments, Ar1 is phenyl. The -S-CH2- groups can be positioned at
1,2- ; 1,3-; or 1,4-positions of the phenyl group. In one particular embodiment, the -S-CH2- groups are positioned at 1,2-positions, i.e., the phenyl group is 1,2-disubstituted. In other embodiments, Ar1 is phenyl having one, two, three, or four, typically one, two, or three, often one or two, and most often one substituent(s). Exemplary substituents suitable for Ar1 include, but are not limited to, halides (e.g., F, Cl, I, or Br), C1-C10 alkyl (e.g., methyl, ethyl, t-butyl, isopropyl, etc.), C1-C10 haloalkyl (e.g., -CF3 etc.), nitro, nitroso, -COnR (where n is 1 or 2 and R is hydrogen or alkyl), cyano, -OR (where R is H, alkyl, carbonyl, etc.), as well as other electron donating or electron withdrawing groups known to one skilled in the art.
[0060] Yet in other embodiments, linker L2 comprises a functional group that is capable of releasing Y2-Z in vivo. In this manner, the moiety Y2-Z is released in vivo thereby exerting its therapeutic activity. Suitable functional groups that is capable of releasing Y2-Z depends on the nature of the function group on moiety Y2 that is linked to the linker L2. For example, when the function group on Z is a hydroxyl group (i.e., Y2 is -OH) or an amino group (Y2 is -MB), the functional group on L2 can be a carboxylate such that an ester bond or an amide bond,
respectively, is formed between the medically useful compound and linker L2. If the functional group (i.e., “Y2”) on the medically useful compound is a carboxylic acid, the corresponding functional group on L2 can be a hydroxyl group or an amino group to form an ester bond or an amide bond, respectively. Other suitable functional groups on L2 that is capable releasing the medically useful compound in vivo are well known to one skilled in the art including a disulfide bond linkage, an ester linkage, a thiol-maleimide linkage, and the like.
[0061] Still yet in other embodiments, the medically useful compound is a therapeutic agent. Suitable therapeutic agents include those that are known to one skilled in the art for treatment of cancer, autoimmune disease (e.g., rheumatoid arthritis), viral infection (e.g., HIV infection), etc. Exemplary therapeutic agents that are useful in compounds of the invention include, but are not limited to, Altretamine; Asparaginase; Bleomycin; Busulfan; Carboplatin; Carmustine; Chlorambucil; Cisplatin; Cladribine; Cyclophosphamide; Cytarabine; Dacarbazine; Diethylstilbestrol; Eribulin, Ethinyl; estradiol; Etoposide; Mitomycin; Mitotane; Mitoxantrone; Paclitaxel; Pentastatin; Pipobroman; Plicamycin; Prednisone; Procarbazine; Streptozocin; Tamoxifen; Teniposide; Vinblastine; Vincristine, daunorubicin, doxorubicin, docetaxel, irinotecan, monomethyl auristatin E, mertansine, SN-38, tesirine, tubulysin, vinca alkaloids, and an analog or derivative thereof, HIV protease inhibitors, HIV fusion inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV entry inhibitors, and therapeutics for autoimmune diseases.
[0062] L2 can be any biocompatible bifunctional linker such as polyethylene glycol
(PEG), e.g., in the form of H2N-CH2CH2-(PEG)m-CH2CH2-COOH, HOOC-CH2CH2-(PEG)m- CH2CH2-COOH, or H2N-CH2CH2-(PEG)m-CH2CH2-NH2, natural and unnatural amino acids or a polyamino acid (PAA), where m is an integer from 0 to 100, typically 1 to 50, often 1 to 25, and more often 1 to 10. Generally, when L2 is a polymer (e.g., PEG, PAA), the total number of monomers within the chain is from about 2 (i.e., a monomer) to about 20, typically from about 2 to about 15, often from about 3 to about 10, and most often from about 4 to about 6.
[0063] Still yet in other embodiments, medically useful compound is a diagnostic or imaging agent, such as a radioactive agent, fluorescent agent, etc. Such imaging agents are well known to one skilled in the art. For example, contrast agents for magnetic resonance imaging
agents, ultrasound contrast agents, and radio contrast agents. See, for example, en.wikipedia.org/wiki/ Contrast_agent.
[0064] Still further, combinations of the various groups described herein can form other embodiments. In this manner, a variety of compounds are embodied within the present invention. By combining various groups described herein in different manner, compounds such as those of the formulas IA and IB are included within the scope of the invention:
IA where a, b, AA1, X1, AA2, AA3, L1, Q, and Ar1 are those defined herein, and
IB where a, b, AA1, X1, AA2, AA3, AA4, Y1, Y2, L1, L2, Z, and Ar1 are those defined herein.
[0065] Some specific examples of compounds of the invention include, but are not limited to, Compound of Formula A, Compound of Formula B, Compound of Formula C, Compound of Formula D, Compound of Formula E, Compound of Formula F, Compound of Formula G, Compound of Formula H, Compound of Formula I, Compound of Formula J, Compound of Formula K, Compound of Formula L, Compound of Formula M, Compound of Formula N, Compound of Formula O, and Compound of Formula P, each of which can also be labelled with deuterium (e.g., Compound of Formulas A-D12, B-D12, C-D12, etc.) or tritium (e.g., Compound of Formulas A-T12, B-T12, C-T12, ..., P-T12). Synthesis of these compounds are provided in the Examples section.
[0066] It should be appreciated that throughout this disclosure combinations of different embodiments described herein form other preferred embodiments. For example, one particular embodiment is described herein as “a” being 0, and another embodiment is described herein where AA1 is homocysteine. Thus, combination of these two embodiments provides compound of Formulas I, IA, and IB, where a is 0 and AA1 is homocysteine.
[0067] Another aspect of the invention provides a diagnostic kit comprising a high affinity CXCR4 selective binding ligand peptide conjugate described herein where the medically useful compound is a diagnostic agent.
[0068] Yet another aspect of the invention provides a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carrier can include a diluent, an excipient, a flavoring agent, an adjuvant, a binder, a stabilizer, coloring agent, or a combination thereof. Generally, “pharmaceutically acceptable carrier” refers to any excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use.
[0069] The present invention includes pharmaceutical compositions comprising at least one compound of the invention, or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
[0070] In general, the compounds of the invention are administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, typically 1-100 mg daily, and often 1-30 mg daily, depending on numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved. One of ordinary skill in the art of treating such diseases is typically able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of the invention.
[0071] Typically, compounds of the invention are administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by
inhalation or insufflation. Typical manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
[0072] A compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, can be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms can be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms can contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions can be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use. Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
[0073] The compounds of the invention can be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms can comprise a compound or compounds of the invention or pharmaceutically acceptable salts thereof as the active component. The pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the
active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be as solid forms suitable for oral administration.
[0074] Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions can be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and can contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
[0075] The compounds of the invention can also be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and can be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi dose containers with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and can contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
[0076] The compounds of the invention can be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions can be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
[0077] The compounds of the invention can be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
[0078] The compounds of the invention can also be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
[0079] The compounds of the invention can be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations can be provided in a single or multidose form. In the latter case of a dropper or pipette, this can be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this can be achieved for example by means of a metering atomizing spray pump.
[0080] The compounds of the invention can be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size can be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, di chi orodifluorom ethane, tri chi orofluorom ethane, or
dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol can conveniently also contain a surfactant such as lecithin. The dose of drug can be controlled by a metered valve. Alternatively, the active ingredients can be provided in a form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier typically forms a gel in the nasal cavity. The powder composition can be presented in unit dose form, for example, in capsules or cartridges of e.g., gelatine or blister packs from which the powder can be administered by means of an inhaler.
[0081] When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compounds of the invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary or desired and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to a skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (l-dodecylazacycloheptan-2-one). Sustained release delivery systems can be inserted subcutaneously into the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
[0082] The pharmaceutical preparations are typically in unit dosage forms. In such form, the preparation is often subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
[0083] Other suitable pharmaceutical carriers and their formulations are described in
Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pa.
[0084] When it is possible that, for use in therapy, therapeutically effective amounts of a compound of Formula I, as well as pharmaceutically acceptable salts thereof, can be
administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the disclosure further provides pharmaceutical compositions, which include therapeutically effective mounts of compounds of Formula I or pharmaceutically acceptable salts thereof or a prodrug thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or simultaneously. The compounds of Formula I and pharmaceutically acceptable salts thereof, are as described above. The carrier(s), diluent(s), or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the disclosure there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of Formula I, or a pharmaceutically acceptable salt thereof or a prodrug thereof, with one or more pharmaceutically acceptable carriers, diluents, or excipients.
[0085] When the compositions of this disclosure comprise a combination of a compound of the present disclosure and one or more additional therapeutic or prophylactic agent, both the compound and the additional agent are usually present at dosage levels of between about 10 to 150%, and more typically between about 10 and 80% of the dosage normally administered in a monotherapy regimen.
[0086] Still another aspect of the invention provides a method for imaging cancer cells in a patient comprising administering to a patient an imaging effective amount of a high affinity CXCR4 selective binding ligand peptide conjugate of Formula I, the medically useful compound is an imaging agent, and imaging cancer cells in said patient using an imaging apparatus. The imaging apparatus used depends on the nature of imaging agent of compound of Formula I. For example, if the imaging agent is a positron-emitting radioisotope, then the imaging apparatus used is a PET scan, and when the medically useful compound is a contrasting agent, then the imaging apparatus can be a computed topography apparatus or an MRI apparatus. When the medically useful compound is a radioactive isotope, the imaging apparatus can be an x-ray machine or other similar device.
[0087] One particular aspect of the invention provides a method for treating cancer in a patient. The method comprises administering a therapeutically effective amount of a compound
of Formula I (where the medically useful compound is a cancer drug) or a pharmaceutical composition comprising a compound of Formula I (where the medically useful compound is a cancer drug) to a cancer patient.
[0088] Another particular aspect of the invention provides a diagnostic or an imaging kit comprising a high affinity CXCR4 selective binding ligand peptide conjugate (PC) of Formula I, where the medically useful compound is a diagnostic agent or an imaging agent, respectively.
[0089] Still another particular aspect of the invention provides a method for treating a patient suffering from rheumatoid arthritis, pulmonary fibrosis, HIV infection, or a cancer. The method includes administering a therapeutically effective amount of a compound of Formula I to a patient in need of treatment thereof. In this method, the medically useful compound of compound of Formula I is a therapeutic agent that can be used to treat the particular clinical condition to be treated. Some of the cancers that can be treated using compounds of the invention include, but are not limited to, breast cancer, pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non-Hodgkin’s lymphoma, lung cancer, ovarian cancer, colorectal cancer, multiple myeloma, glioblastoma multiforme, and chronic lymphocytic leukemia.
[0090] Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting. In the Examples, procedures that are constructively reduced to practice are described in the present tense, and procedures that have been carried out in the laboratory are set forth in the past tense.
EXAMPLES
[0091] The following abbreviations are used: Ac: acetyl; Boc: tert-butyloxycarbonyl;
BOP: (benzotriazol-l-yloxy)-tris(dimethylamino) phosphonium hexafluorophosphate; Bz: benzoyl; Bzl: benzyl; Dab: 1,4-diaminobutyric acid; Dap: 1,3-diaminopropionic acid; DCC: dicyclohexyl-carbodiimide; DCM: dichloromethane; DIC: diisopropyl carbodiimide; DIEA: diisopropyl-ethylamine; DMAP: 4-(N, A-di methyl ami no)pyri di ne; DMF: A' A -di methyl formamide; DMSO: dimethyl-sulfoxide; EDT: 1,2-ethane-dithiol; Et: ethyl; Fmoc: 9-fluor- enylmethoxy carbonyl; HATU: N-[(dimethylamino)-lH-l,2,3-triazolo[4,5-b]pyridin-l-
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide; HBTU: O-benzo- triazolyl-A, A, /V’,/V’-tetramethyluronium hexafluorophosphate; HCTU: lH-benzotriazo-lium 1- [bis(dimethylamino)methylene]-5-chloro-3-oxide hexafluorophosphate; HOBt: hydroxybenzotriazole; hCys: homocysteine; iPr: isopropyl; IPA: isopropyl alcohol; Me: methyl; Mmt: 4-mthoxytrityl; Mpa: 3-mercaptopropionic acid; 2Nal: 2-naphthylalanine; INal: 1- naphthylalanine; NMM: N-methylmorpholine; NMP: N-m ethyl -pyrrol i done; Orn: ornithine; Pbf: 2,2,4,6,7-pentamethyl-dihydrobenzofurane-5-sulfonyl; PBS: phosphate buffered saline; PyBOP: (benzotriazol-l-yloxy)-tris(pyrrolidino)-phosphonium hexafluoro-phosphate; PyBrOP: bromotris(pyrrolidino)phosphonium hexafluorophosphate; tBu: tert-butyl; TFA: trifluoroacetic acid; TFE: trifluroethanol; THF: tetrahydrofuran; TIS: triisopropyl silane; Trt: trityl; niini- PEG6: 6-mer of ethylene glycol; all common amino acids are expressed as three letter symbols or otherwise specified.
[0092] Mass Spectroscopy (MS) Analysis: Preparation of compounds of the present invention as described in the following examples is meant to be illustrative rather than limiting. In each of these examples, the observed molecular weight is reported as a de-convoluted value. The de-convoluted value is derived from the formula MW (observed) = n(m/z)-n, where m/z represents the charged ion (positive mode) and n is the number of charges of the specific species. When multiple charged species are present in the mass spectrum, the observed molecular weight is reported as an average.
[0093] General Method of Peptide Synthesis, Cyclic Structure Formation, and Salt
Exchange: Peptides were synthesized using solid phase peptide synthesis chemistry known in the art. The cyclic structure of those peptides was established, for a disulfide, by using air oxidation, or iodine oxidation in the presence of acidic acid, or for a bisthioether ring, by nucleophilic substitution using a bis(halomethyl) aryl compound, typically using 1.3 equivalents of a bis(bromom ethyl) aryl compound, in the presence of a base, such as 15 mM ammonium bicarbonate solution.
[0094] While the present invention illustrates preparation of one particular peptide linkage, other peptide linkages that are within the scope of the present invention can be readily prepared using procedures disclosed in, for example, commonly assigned U.S. Patent Application Nos. 15/898,434, filed February 17, 2018, and 15/695,862, filed September 5, 2017,
both of which are incorporated herein by reference in their entirety. Furthermore, other peptides linkages that are within the scope of the present invention can readily be prepared by one skilled in the art having read the present disclosure along with the commonly assigned U.S. patent applications that are incorporated by reference herein.
To a 0 °C solution of 500 mg of paclitaxel (0.6 mmole) in 80 mL of DCM and 0.06 mmole of DMAP (9.2 mg) was added a solution of 1.1 mmole of 2-bromoacetic acid (100.3 mg) in 50 mL of DCM followed by 3 eq. of DIC (0.3 mL) under stirring. The reaction mixture was then slowly warmed up to room temperature and the coupling reaction was allowed to proceed at 30 °C for one hour under continuous stirring. Crude product of 2’-bromoacetyl-paclitaxel was purified and lyophilized before conjugation to cyclized CXCR4 antagonist peptide (MW MS: observed 975.10; calculated: 974.85).
[0096] Purification, Salt Form Conversion, and Final Product Characterization:
Final products were purified by reverse phased HPLC and further characterized by analytical HPLC and mass spectroscopy. Peptides purified from reverse phased HPLC were usually in trifluoroacetic acid (TFA) form. This salt was typically converted to a more pharmaceutically friendly salt form, such as acetic acid or hydrochloric acid salt form. Converting a peptide in TFA salt to a hydrochloric acid salt could be achieved by repeated lyophilization of the peptide in TFA salt in a dilute hydrochloric acid solution. For conversion of a peptide in TFA salt to an acetate salt, typically the following process was used. Strong anion exchange resin (chloride form, substitution 3 mmole/g, water content 50%, using 2 grams of resin per gram of peptide) was first washed three times with milli Q water, then three times with 1 N NaOH solution three times, 5 min/time, and then five times with milli Q water, 5 min/time. The resin was further
washed with 75% ethanol water until the pH reaches about 7.4. This resin was treated with 10% acetic acid solution three times, five minutes each time. The resin was then washed with 1% acetic acid solution three times, five minutes each time. The resin was ready for the salt conversion of the purified peptide.
[0097] The purified, lyophilized peptide was dissolved in 1% acetic acid solution and added to the prepared resin described above. The mixture was agitated or magnetically stirred at room temperature for 1 h. The supernatant was separated. The resin was washed three times with 1% acetic acid solution. The supernatant and the washing solution were combined, filtered through a 0.22 pm membrane and lyophilized, to afford a peptide in acetate salt.
[0099] Peptide chain assembly. Fmoc-Cys(Mmt)-Tyr(tBu)-Lys(iPr,Boc)-(D-Arg(Pbf))-
2Nal-Gly-Cys(Mmt)-Lys(iPr,Boc)-(mini-PEG6)-Cys(Trt)-Sieber Amide AM Resin (SEQ ID NO: 5)
(SEQ ID NO: 6)
Compound B
[0100] The peptide chain was assembled by standard Fmoc chemistry using Sieber amide
AM resin (Xi’an LanXiao Chemical Limited, Xi’an, China). Briefly, 40 g of Sieber amide AM resin was swollen in 300 mL of DCM for 2 h and then washed four times with DMF. Removal of Fmoc was carried out in 250 mL of 20% piperidine in DMF for 20 min at room temperature and washed several times with DMF. Ninhydrin test was negative. Stepwise chain assembly started with Fmoc-Cys(Trt)-OH from the C-terminal end of the linear peptide. Three equivalents of protected amino acid Fmoc-Cys(Trt)-OH were activated with DIC/HOBt in 80 mL of DMF, and coupled to the Fmoc-removed Sieber amide AM resin prepared above for 2 h at room temperature. Ninhydrin test was negative. Capping of the non-reacted amino group was performed for 30 min with 160 mL of a mixture of acetic anhydride/DIEA/DCM at a volume ratio of 1 : 1 :4. This was followed by Fmoc removal using 250 mL of 20% piperidine in DMF for 20 min. The following residues were coupled sequentially without capping: Fmoc-(mini-PEG6)- OH, Fmoc-Lys(iPr,Boc)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Gly-OH, Fmoc-2Nal-OH, Fmoc-D- Arg(Pbf))-OH, Fmoc-Lys(iPr,Boc)-OH, Fmoc-Tyr(tBu)-OH, and Fmoc-Cys(Mmt)-OH. After the coupling of last residue Fmoc-Cys(Mmt), Fmoc protection was removed again using 250 mL of 20% piperidine in DMF for 20 min. N-terminal acetylation was carried out with 160 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room temperature. The resin was then washed with 250 mL of DMF three time and then with 250 mL of DCM three times, then dried under vacuum to afford 81 grams of peptide resin containing the assembled target linear peptide. The dried resin was divided into several portions and one portion (20 grams) is used in the following operation.
[0101] Removal of Mmt protection on Cys residues and Cleavage of partial protected linear peptide from peptide resin 20 grams of above peptide resin was swelled in 300 mL of DCM for 30 min. Total 1000 mL of a cleavage/deprotection cocktail (TFA/H2O/EDT/TIS/DCM, 6:3:1.5:3:86.5, v/v) was added to above swelled resin to remove Mmt protection of Cys side chain. The mixture was stirred for 20 min at room temperature. This deprotection and cleavage procedure was repeated once using another 1000 mL of the cleavage/deprotection cocktail above at room temperature for 20 min. After removal of the solid resin by filtration, the cleavage solutions containing the partially deprotected linear peptide were combined and concentrated under vacuum using a rotary evaporator. The residues (crude peptide) were then lyophilized to afford 9.5 grams of partially deprotected crude linear peptide.
[0102] Cyclization. To a solution of 2.2 grams of above crude linear peptide in 110 mL of DMF was added 20 mL of MeCN containing 368 mg of l,2-bis(bromomethyl) benzene. The solutions were mixed well, then 1630 mL of MeCN and 440 mL of water were added. The pH of this reaction mixture was adjusted to pH 8~9 using 1 M of ammonium carbonate solution. The cyclization reaction was allowed to proceed for 1 h at room temperature. The reaction was monitored by MS. The reaction mixture was then divided into six equal portions and lyophilized.
[0103] Side chain deprotection of the cyclized peptide : The lyophilized crude cyclized peptide was deprotected using a cleavage cocktail (TFA/EDT/TIS/H20/thioanisole/phenol, per 100 mL of solution contains 81.5 mL TFA, 2.5 mL EDT, 1.5 mL TIS, 5.0 mL H2O, 5.0 mL thioanisole, and 5.0 grams phenol) at 10 mL each container, for 60 min at 30 °C. To the cleavage mixture was added 4 volumes of cold ethyl ether. The crude peptide precipitates were separated by centrifugation at 3000 rpm for 2 min. The crude peptide precipitates were washed three times with ethyl ether. The crude peptide was purified to a purity >90% on preparative HPLC, and lyophilized (MW MS: observed 1719.55; calculated: 1720.18).
[0104] Preparation ofPDC CXCR4 peptide-paclitaxel drus Conjugate: Above prepared 452 mg of 2’-bromoacetyl-paclitaxel and 905 mg of cyclized CXCR4 peptide were dissolved in 100 mL of MeCN/water (1:1, v/v). The solution was adjusted to pH 7-7.5 using 0.5M of ammonium bicarbonate. The conjugation reaction was completed in about half an hour as confirmed by MS at room temperature. The final product was purified using a reverse-phased
preparative column Daisogel (50x250mm, 8pm); mobile phases - Solvent A: 0.1% TFA water; Solvent B: 0.1% TFA acetonitrile. Fractions containing the target product MB1707 were combined and lyophilized (a TFA salt). Salt exchange as described above afforded a peptide in acetate salt. Analytical HPLC purity of the final peptide product is 99.61%; MW cal.: 2614.12 Da; MW obs.: 2613.30Da.
[0105] Example 2: Synthesis of Isotopically labelled compound A-D 12
[0106] Peptide chain assembly: Fmoc-Cys(Mmt)-Tyr(tBu)-Lys(Boc)-(D-Arg(Pbf))-
(SEQ ID NO: 8)
Compound B-D12
[0107] The peptide chain was assembled by standard Fmoc chemistry using Sieber amide
AM resin (Xi’an LanXiao Chemical Limited, Xi’an, China). Briefly, 1.5 grams of Sieber amide AM resin was swollen in 30 mL of DCM for 2 h and then washed four times with 25 mL of DMF. Removal of Fmoc was carried out in 25 mL of 20% piperidine in DMF for 20 min at room temperature and washed several times with DMF. Ninhydrin test was negative. Stepwise chain assembly started with Fmoc-Cys(Trt)-OH from the C-terminal end of the linear peptide. Three equivalents of protected amino acid Fmoc-Cys(Trt)-OH (702 mg) were activated with DIC (1 mL)/HOBt (243 mg) in 5 mL of DMF, and coupled to the Fmoc-removed Sieber amide AM resin prepared above in a temperature controlled oven at 30 °C overnight. The reaction mixture was drained and the resin was washed several times with 25 mL of DMF. Capping of the non- reacted amino group was performed for 30 min with 16 mL of a mixture of acetic
anhydride/DIEA/DCM at a volume ratio of 1 : 1 :4. Ninhydrin test was negative. This was followed by Fmoc removal using 25 mL of 20% piperidine in DMF for 20 min.
[0108] The following residues were coupled sequentially without the capping step:
Fmoc-(mini-PEG6)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Gly-OH, Fmoc- 2Nal-OH, Fmoc-D-Arg(Pbf))-OH, Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)-OH, and Fmoc- Cys(Mmt)-OH. After the coupling of last residue Fmoc-Cys(Mmt), Fmoc protection was removed again using 25 mL of 20% piperidine in DMF for 20 min. N-terminal acetylation was carried out with 16 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room temperature. The peptide resin was then washed with 25 mL of DMF three time and followed by 25 mL of DCM three times, then the peptide resin dried under vacuum to afford 2.8 grams of peptide resin containing the assembled target linear peptide.
[0109] Removal of Mmt protection on Cys residues and Cleavage of partial protected linear peptide from peptide resin: 2.8 grams of above peptide resin was swelled in 30 mL of DCM for 30 min. 150 mL of a cleavage/deprotection cocktail (TFA/FLO/EDT/TIS/DCM, 6:3:1.5:3:86.5, v/v) was added to above swelled resin to remove Mmt protection of Cys side chain, 20 min at room temperature. The supernatant of the cleavage mixture was drained into a flask containing 150 mL of water. This deprotection and cleavage procedure was repeated once using another 150 mL of the cleavage/deprotection cocktail above at room temperature for 20 min. After removal of the solid resin by filtration, the cleavage solutions containing the partially deprotected linear peptide were combined and concentrated under vacuum using a rotary evaporator. The residues (crude peptide) were then lyophilized to afford 1.2 grams of partially deprotected crude linear peptide.
[0110] Cyclization. To a solution of 1.2 grams of above crude linear peptide in 60 mL of
DMF was added 10 mL of MeCN containing 200 mg of l,2-bis(bromomethyl) benzene. The solutions were mixed well, then 890 mL of MeCN and 240 mL of water were added. The pH of this reaction mixture was adjusted to pH 8~9 using 1 M of ammonium carbonate solution. The cyclization reaction was allowed to proceed for 1 h at room temperature under magnetic stirring. The completion of cyclization was confirmed by MS. The reaction mixture was then divided into three equal portions and lyophilized in a flask.
[0111] Side chain deprotection of cyclized peptide : To each of the lyophilized crude cyclized peptide flask was added 10 mL of a cleavage cocktail composed of TFA/EDT/TIS/H2O/ thioani sol e/phenol (per 100 mL of solution contains 81.5 mL TFA, 2.5 mL EDT, 1.5 mL TIS,
5.0 mL FLO, 5.0 mL thioanisole, and 5.0 grams phenol). The cleavage reaction was allowed to proceed for 60 min at 30 °C. To the cleavage mixture was added 4 volumes of cold ethyl ether. The crude peptide precipitates were separated by centrifugation at 3000 rpm for 2 min. The crude peptide precipitates were washed three times with icy cold ethyl ether. The crude peptide was dried under vacuum and then used for lysine side chain modification as following without further purification.
[0112] Lysine side chain modification using acetone-D6: 125 mg of crude product from above was dissolved in 12.5 mL of a solution composed of acetic acid:acetone-D6:ethanol (2:2:8.5, v/v), then 324 mg of sodium cyanoboronhydride (NaBFLCN) was added under stirring. The reductive amination was allowed to proceed at 30 °C for 2h. The reaction mixture was diluted with water and loaded onto a preparative HPLC column. The isotopically labeled cyclic peptide was purified to a purity >90% and lyophilized.
Compound A-D12
[0114] Above prepared 452 mg of 2’-bromoacetyl-paclitaxel and 905 mg of cyclized
CXCR4 peptide were dissolved in 100 mL of MeCN/water (1:1, v/v). The solution was adjusted
to pH 7-7.5 using 0.5M of ammonium bicarbonate. The conjugation reaction was completed in about half an hour as confirmed by MS at room temperature. The final product was purified using a reverse-phased preparative column Daisogel (50x250mm, 8pm); mobile phases - Solvent A: 0.1% TFA water; Solvent B: 0.1% TFA acetonitrile. Fractions containing the target product MB1707-D12 were combined and lyophilized (a TFA salt). Salt exchange as described above afforded a peptide in acetate salt. Analytical HPLC purity of the final peptide product is 99.01%; MW cal.: 2626.20 Da; MW obs.: 2623.35 Da.
[0115] Example 3. Synthesis of Cyclic fAc-HCvs-Tyr-Lvs(iPr)-d-Ars-2Nal-Glv-Cysl -
Compound C
[0116] The sequence hCys(Trt)-Tyr(tBu)-Lys(iPr, Boc)-(D-Arg(Pbf))-2Nal-Gly-
Cys(Trt)-Lys(iPr, Boc)-PEG6 (SEQ ID NO: 11) was assembled by standard Fmoc chemistry using 2-chlorotrityl chloride resin. Briefly, 4.0 grams of the resin was swollen in DCM for 2 h, washed four times with DMF and then once with DCM. The loading of the first residue Fmoc- PEG6 was carried out in DCM using four equivalents of amino acid activated with five equivalents of DIEA. The coupling at room temperature for 1.5 h was followed by capping of
the unreacted substitution sites with methanol/DIEA (1:1, v/v, 24 mL) for 30 min. Removal of Fmoc protection was carried out in 20% piperidine in DMF for 20 min at room temperature and washed several times with DMF. Ninhydrin test was negative. Stepwise chain assembly of the linear peptide using standard Fmoc chemistry was continued consequentially through a cycle of deprotection, activation and coupling.
[0117] After the coupling of last residue Fmoc-hCys(Trt)-OH, Fmoc protection was removed again using 20% piperidine in DMF for 20 min. N-terminal acetylation was carried out with 5 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room temperature. The resin was then washed with DMF three time and then with DCM twice, dried under vacuum.
[0118] The crude linear peptide cleavage and side chain protections were carried out using 10 mL of a cleavage cocktail of TFA/EDT/TIS/FLO/thioanisol e/phenol per gram of crude peptide resin (per 100 mL of solution contains 81.5 mL TFA, 2.5 mL EDT, 1.0 mL TIS, 5.0 mL FLO, 5.0 mL thioanisole, and 5.0 grams phenol) for 70 min at room temperature. Then to the cleavage mixture was added eight volumes of methyl t-butyl ether. The crude peptide precipitates were separated by centrifugation at 3000 rpm for 3 min. The crude peptide precipitates were washed three times with methyl t-butyl ether. The crude peptide was then dissolved in an aqueous acetonitrile and lyophilized.
[0119] The crude lyophilized product was used directly in the cyclization reaction. The lyophilized crude peptide was dissolved in 20% acetic acid at 0.5 mg/mL. Under stirring, add 0.03% mole/L iodine solution until the peptide solution turned light yellow. The solution was protected from visible light during the cyclization. Cyclization was completed within 0.5 h as monitored by mass spectroscopy. The cyclized final product was purified using a reverse-phased preparative column Daisogel (50x250mm, 8pm) with mobile phases - A: 0.1% TFA water; B:
0.1% TFA acetonitrile. Fractions containing the target product were combined and lyophilized (a TFA salt).
[0120] Example 4. Synthesis of cyclic [Ac-hCys-Tyr-Lys(iPr)-d-Ars-2Nal-Gly-Cysl -
Lys(iPr)-PEGfi-Lys, a disulfide ring hCysl-Cys7.
Compound D
[0121] The sequence hCys(Trt)-Tyr(tBu)- Lys(iPr,Boc)-(D-Arg(Pbf))-2Nal-Gly-
Cys(Trt)- Lys(iPr,Boc)-PEG6-Lys(Boc) (SEQ ID NO: 13) was assembled manually by standard Fmoc chemistry using Rink AM resin. Briefly, 3.6 grams of Rink AM resin was swollen in DCM for 14 h and then washed four times with DMF. Removal of Fmoc was carried out in 20% piperidine in DMF for 20 min at room temperature and washed several times with DMF. Ninhydrin test was negative. Stepwise chain assembly started from the C-terminal end of the linear peptide and was accomplished in nine major steps. In step 1, three equivalents of protected amino acid Fmoc-Lys(Boc) were activated with DIC/HOBt in DMF, and coupled to the Fmoc-removed Rink AM resin above for 2 h at room temperature followed by Fmoc removal using 20% piperidine in DMF for 20 min. In step 2, three equivalents of Fmoc-PEG6 acid were activated with DCC/HOBt in DMF and coupled to the deprotected resin from step 1.
Appropriate steps were continued using Fmoc-protected amino acids, respectively, until the coupling of Fmoc-hCys(Trt)-OH.
[0122] After the coupling of last residue Fmoc-hCys(Trt)-OH, Fmoc protection was removed again using 20% piperidine in DMF for 20 min. N-terminal acetylation was carried out with 5 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room
temperature. The resin was then washed with DMF three time and then with DCM twice, dried under vacuum.
[0123] The finished peptide was deprotected and cleaved from the resin using 10 mL/gram of resin of a cleavage cocktail of TFA/EDT/TIS/FLO/thioanisole/ phenol (per 100 mL of solution contains 81.5 mL TFA, 2.5 mL EDT, 1.0 mL TIS, 5.0 mL FLO, 5.0 mL thioanisole, and 5.0 grams phenol) for 70 min at room temperature. To the cleavage mixture was added eight volumes of methyl t-butyl ether. The crude peptide precipitates were separated by centrifugation at 3000 rpm for 3 min. The crude peptide precipitates were washed three times with methyl t- butyl ether. The crude peptide was then dissolved in aqueous acetonitrile and lyophilized.
[0124] The crude lyophilized product was used directly in the cyclization reaction. The lyophilized crude peptide was dissolved in water containing 20% acetic acid at 0.5 mg/mL (500 mg of crude peptide in one liter). Under stirring, 0.03% mole/L iodine solution was added to the peptide solution until the solution became pale yellow. Cyclization was complete within 0.5 h in dark as monitored by mass spectroscopy. The cyclized final product was purified using a reverse-phased preparative column Daisogel (50x250mm, 8pm); mobile phases - Solvent A:
0.1% TFA water; Solvent B: 0.1% TFA acetonitrile. Fractions containing the target product were combined and lyophilized (a TFA salt).
[0125] Example 5. cyclic I A cetyl-hCys- Tyr-Lysf iPr) -d-Arg-2Nal-Gly-Cys 1-Lvs( iPr) - mini-P EG fi-Cys- Amide, a disulfide ring hCysl-Cys 7
Compound E
[0126] The sequence hCys(Mmt)-Tyr(tBu)- Lys(iPr,Boc)-(D-Arg(Pbf))-2Nal-Gly-
Cys(Mmt)- Lys(iPr,Boc)-PEG6-Cys(Trt) (SEQ ID NO: 15) was assembled by standard Fmoc chemistry using Sieber amide AM resin (Xi’an LanXiao Chemical Limited, Xi’an, China). Briefly, 4 g of Sieber amide AM resin was swollen in 30 mL of DCM for 2 h and then washed four times with DMF. Removal of Fmoc was carried out in 25 mL of 20% piperidine in DMF for 20 min at room temperature and washed several times with DMF. Ninhydrin test was negative. Stepwise chain assembly started with Fmoc-Cys(Trt)-OH from the C-terminal end of the linear peptide. Three equivalents of protected amino acid Fmoc-Cys(Trt)-OH were activated with DIC/HOBt in 8 mL of DMF, and coupled to the Fmoc-removed Sieber amide AM resin prepared above for 2 h at room temperature. Ninhydrin test was negative. Capping of the non-reacted amino group was performed for 30 min with 16 mL of a mixture of acetic anhydride/DIEA/DCM at a volume ratio of 1 : 1 :4. This was followed by Fmoc removal using 25 mL of 20% piperidine in DMF for 20 min. The following residues were coupled sequentially without capping: Fmoc- (mini-PEG6)-OH, Fmoc-Lys(iPr,Boc)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Gly-OH, Fmoc-2Nal- OH, Fmoc-D-Arg(Pbf))-OH, Fmoc-Lys(iPr,Boc)-OH, Fmoc-Tyr(tBu)-OH, and Fmoc- hCys(Mmt)-OH. After the coupling of last residue Fmoc-hCys(Mmt), Fmoc protection was
removed again using 25 mL of 20% piperidine in DMF for 20 min. N-terminal acetylation was carried out with 16 mL of a mixture of acetic anhydride/DIEA/DMF (1 : 1 :4, v/v/v) for 30 min at room temperature. The resin was then washed with 25 mL of DMF three time and then with 25 mL of DCM three times, then dried under vacuum to afford 8 grams of peptide resin containing the assembled target linear peptide. The dried resin was used in the following operation.
[0127] Removal of Mmt protection on Cys residues and Cleavage of partial protected linear peptide from peptide resin About 2 grams of above peptide resin was swelled in 30 mL of DCM for 30 min. Total 100 mL of a cleavage/deprotection cocktail (TFA/FLO/EDT/TIS/DCM, 6:3:1.5:3:86.5, v/v) was added to above swelled resin to remove Mmt protection of Cys side chain. The mixture was stirred for 20 min at room temperature. This deprotection and cleavage procedure was repeated once using another 100 mL of the cleavage/deprotection cocktail above at room temperature for 20 min. After removal of the solid resin by filtration, the cleavage solutions containing the partially deprotected linear peptide were combined and concentrated under vacuum using a rotary evaporator. The residues (crude peptide) were then lyophilized to afford about 1 gram of partially deprotected crude linear peptide.
[0128] The crude lyophilized product was used directly in the cyclization reaction. The lyophilized crude peptide was dissolved in water containing 20% acetic acid at 0.5 mg/mL (500 mg of crude peptide in one liter). Under stirring, 0.03% mole/L iodine solution was added to the peptide solution until the solution became pale yellow. Cyclization was complete within 0.5 h in dark as monitored by mass spectroscopy. The cyclization reaction was allowed to proceed for 1 h at room temperature. The reaction mixture was then divided into several equal portions and lyophilized.
[0129] Side chain deprotection of the cyclized peptide : The lyophilized crude cyclized peptide was deprotected using a cleavage cocktail (TFA/EDT/TIS/FLO/thioanisole/phenol, per 100 mL of solution contains 81.5 mL TFA, 2.5 mL EDT, 1.5 mL TIS, 5.0 mL FLO, 5.0 mL thioanisole, and 5.0 grams phenol) at 10 mL each container, for 60 min. To the cleavage mixture was added 4 volumes of cold ethyl ether. The crude peptide precipitates were separated by centrifugation at 3000 rpm for 2 min. The crude peptide precipitates were washed three times with ethyl ether. The crude peptide was purified to a purity >90% on preparative HPLC, and lyophilized.
[0130] Example 6. Preparation ofPDC CXCR4 peptide conjugate Compound F
Compound F
[0131] Above prepared 450 mg of 2’-bromoacetyl-paclitaxel and 905 mg of cyclized
CXCR4 peptide Compound C are dissolved in 100 mL of MeCN/water (1:1, v/v). The solution is adjusted to pH 7-7.5 using 0.5M of ammonium bicarbonate. The conjugation reaction is monitored by MS and the reaction completed in about half an hour. The final product is purified using a reverse-phased preparative column Daisogel (50x250mm, 8pm); mobile phases - Solvent A: 0.1% TFA water; Solvent B: 0.1% TFA acetonitrile. Fractions containing the target product Compound F are combined and lyophilized (a TFA salt). Salt exchange as described above affords a peptide in acetate salt.
[0132] Example 7. Preparation of Compounds G-P.
[0133] Compounds G-P are prepared in a similar fashion starting with a Rink amide resin or 2-chlorotrityl resin or a Sieber amide AM resin using standard Fmoc solid phase peptide chemistry.
Compound H
Compound L
Compound N
Compound P
[0134] Example 8. Synthesis of isotopically labelled compounds
[0135] Using the procedures described in Examples above and using a corresponding deuterated compound B-D12 or a corresponding tritium labelled compound (i.e., compound B- T12, for tritium labelled compound of B, similar to B-D12 but where deuterium are replaced with tritium) deuterated or tritium labelled cyclic peptide moieties are prepared. Use of these deuterium labelled (B-D12) and tritium labelled (B-T12) compounds provide synthesis of corresponding deuterium labelled (“-D12”) and tritium labelled (i.e., “-T12”) compounds A-P, i.e., compounds A-D12, A-T12, B-D12, B-T12, C-D12, C-T12, P-D12, and P-T12
[0136] Human CXCR4/1251-SDF- 1 a Binding Inhibition Assay (Performed by
EUROFINS CEREP SA, Le Bois l’Eveque, 86600 Celle L'Evescault, France): Human chemokine receptor CXCR4 expressed in Chem-1 cells were used in modified HEPES buffer pH 7.4. A 0.5 pg (Membrane protein may change from lot to lot, the concentration used will be adjusted if necessary), aliquot was incubated with 0.03 nM [125I]SDF-la for 90 minutes at 25 °C. Non-specific binding was estimated in the presence of 30 nM SDF-Ia. Membranes were filtered and washed, filters were then counted to determine [125I]SDF-la specifically bound.
Compounds were screened starting at 10 pM with 11-point dilutions (Valenzuela-Fernandez A, et al. J Biol Chem. 277(18): 15677, 2002). The CXCR4 binding affinity of the antagonist peptides disclosed herein and their drug-conjugates is 1.0 pM or less to be practical for therapeutic use.
[0137] The foregoing discussion of the invention has been presented for purposes of illustration and description. The foregoing is not intended to limit the invention to the form or forms disclosed herein. Although the description of the invention has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter. All references cited herein are incorporated by reference in their entirety.
Claims
What is Claimed is:
1 An isotopically labelled selective CXCR4 binding peptide conjugate (“PC”) of the formula:
I or a pharmaceutically acceptable salt thereof, wherein: a is 0 or 1; b is an integer from 1 to 4;
AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, optionally substituted homocysteine, or optionally substituted penicillamine;
AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine;
Ar1 is an optionally substituted aryl;
X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); each of AA3 is independently Gly, Phe, 2Nal, INal, Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr); and wherein at least one of AA1, X1, AA2, or AA3 comprises a moiety of the formula:
-L3-Q, wherein
L1 is a polymeric linker having a functional group for linking Q, wherein L1 comprises from about 2 to about 20 monomers or copolymers;
Q is absent, AA4, or a moiety of the formula: -[AA4-Y1-L2]C-Y2-Z, wherein c is 0 or 1;
AA4 is an amino acid or a derivative thereof;
Y1 is a side-chain function group of amino acid AA4;
L2 is a non-polymeric linker;
Z a medically useful compound; and
Y2 is a functional group of said medically useful compound or a functional group of L2; and wherein one or more of AA1, AA2, X1, AA3, and AA4 are isotopically labelled with a positron-emitting radioisotope, a radioactive metal isotope, deuterium, tritium, 13C, 14C, 180, or a combination thereof.
2. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein said medically useful compound comprises an imaging, a contrast agent, or a therapeutic agent.
3. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1 of the formula:
IA wherein a, b, AA1, X1, AA2, AA3, L1, Q, and Ar1 are as defined in claim 1.
4. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 3, wherein Q is absent.
5. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 3, wherein Q is AA4, or a moiety of the formula: -[AA^Y^L^c- ^-Z, wherein c, AA4, Y1, L2, Y2, and Z are as defined in claim 3.
6. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein a is 0.
7. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein a is 0.
8. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein AA1 is homocysteine.
9. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim, wherein a is 1.
10. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein X1 is isotopically labelled.
11. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein AA3 is isotopically labelled.
12. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein at least one of X1 and AA3 is isotopic labelled, and wherein said isotopically label comprises deuterium, tritium, 13C, 14C, 180, or a combination thereof.
13. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 10, wherein at least one of X1 and AA3 is isotopic labelled with deuterium or tritium.
14. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein said medically useful compound is a therapeutic agent.
15. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 12, wherein said therapeutic agent is an anticancer agent.
16. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 13, wherein said anticancer agent is selected from the group consisting of paclitaxel, Altretamine, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Diethylstilbestrol, Eribulin, Ethinyl, estradiol, Etoposide, Mitomycin, Mitotane, Mitoxantrone, Pentastatin, Pipobroman, Plicamycin, Prednisone, Procarbazine, Streptozocin, Tamoxifen, Teniposide, Vinblastine, and Vincristine.
17. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1 of the formula:
IB wherein a, b, AA1, X1, AA2, AA3, AA4, Y1, Y2, L2, Z, and Ar1 are as defined in claim 1; and Lla is a polymeric linker comprising from about 2 to about 20 monomers or copolymers
18. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein L2 is a non-polymeric linker of the formula: -CH2-C(=0)-NH-CH2- -CH2-NH-C(=0)-CH2- -(CH2)„-C(=0)-NH-CH2- -(CH2)„-NH-C(=0)-CH2- or-(CH2)n- wherein n = is an integer from 1 to 6.
19. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein AA1 along with the sulfur atom that is attached thereto is optionally substituted cysteine.
20. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 17, wherein a-amino group of AA1 is substituted with an acetyl group.
21. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein AA2 along with the sulfur atom that is attached thereto is optionally substituted cysteine.
22. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein X1 is Lys(iPr) or Lys(deuterated-iPr).
23. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein AA3 is Lys(iPr) or Lys(deuterated-iPr).
24. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein Ar1 is phenyl.
25. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein b is 1.
26. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 23, wherein AA3 is Lys(iPr) or Lys(deuterated-iPr).
27. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 24, wherein L1 is a polymeric linker of the formula: -NH-(CH2)2-[0-CH2-CH2-]n-0- (CH2)2-C(=0)-, wherein n is an integer from 2 to 20, -NH- is attached to the carbonyl carbon of amino acid AA3, and -C(=0)- is attached to a-amino functional group of amino acid AA4.
28. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein AA4 is cysteine, homocysteine, or penicillin amine.
29. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein at least one of AA1, X1, AA2, or AA3 amino acid residue is a (D)-isomer.
30. The isotopically labelled selective CXCR4 binding peptide conjugate according to claim 1, wherein said selective CXCR4 binding peptide conjugate is selected from the group consisting of Compound of Formula A, Compound of Formula B, Compound of Formula C, Compound of Formula D, Compound of Formula E, Compound of Formula F, Compound of Formula G, Compound of Formula H, Compound of Formula I, Compound of Formula J, Compound of Formula K, Compound of Formula L, Compound of Formula M, Compound of Formula N, Compound of Formula O, Compound of Formula P, corresponding deuterium labelled compounds thereof, and corresponding tritium labelled compounds thereof.
31. A method for treating a subject suffering from a cancer, said method comprising administering to the subject a therapeutically effective amount of an isotopically labelled selective CXCR4 binding peptide conjugate of claim 1, wherein said medically useful compound is an anticancer agent.
32. The method of claim 29, wherein said anticancer agent is selected from the group consisting of paclitaxel, Altretamine, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Diethylstilbestrol, Eribulin, Ethinyl, estradiol, Etoposide, Mitomycin, Mitotane, Mitoxantrone, Pentastatin, Pipobroman, Plicamycin, Prednisone, Procarbazine, Streptozocin, Tamoxifen, Teniposide, Vinblastine, and Vincristine.
33. The method of claim 29, wherein said cancer is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, kidney cancer, brain cancer, blood cancer, leukemia, prostate cancer, ovarian cancer, and bladder cancer.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022545389A JP2023516878A (en) | 2020-01-26 | 2020-03-27 | Isotopically labeled selective CXCR4 binding peptide conjugates and methods of making and using the same |
EP20915510.0A EP4097120A4 (en) | 2020-01-26 | 2020-03-27 | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same |
CN202080094623.3A CN115003684A (en) | 2020-01-26 | 2020-03-27 | Isotopically labeled selective CXCR4 binding peptide conjugates and methods of making and using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/752,690 | 2020-01-26 | ||
US16/752,690 US11123437B2 (en) | 2017-09-05 | 2020-01-26 | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021150258A1 true WO2021150258A1 (en) | 2021-07-29 |
WO2021150258A9 WO2021150258A9 (en) | 2021-11-11 |
Family
ID=76992501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/025522 WO2021150258A1 (en) | 2020-01-26 | 2020-03-27 | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4097120A4 (en) |
JP (1) | JP2023516878A (en) |
CN (1) | CN115003684A (en) |
WO (1) | WO2021150258A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080300177A1 (en) * | 2007-05-30 | 2008-12-04 | Wayne David Kohn | Cyclic peptide cxcr4 antagonists |
US20140135381A1 (en) * | 2010-12-29 | 2014-05-15 | Hoffmann-La Roche Inc. | Small molecule conjugates for intracellular delivery of biologically active compounds |
WO2019050564A1 (en) * | 2017-09-05 | 2019-03-14 | Mainline Biosciences | High affinity cxcr4 selective binding conjugate and method for using the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1991562A2 (en) * | 2006-02-27 | 2008-11-19 | Technische Universität München | Cancer imaging and treatment |
US8906355B2 (en) * | 2009-10-29 | 2014-12-09 | Lucia Irene Gonzalez | Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof |
IT1397901B1 (en) * | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | CYCLIC PEPTIDES THAT BIND THE CXCR4 RECEPTOR AND THEIR USE IN MEDICAL AND DIAGNOSTIC FIELDS. |
CN102626522B (en) * | 2012-04-12 | 2014-09-10 | 韩彦江 | Polypeptide radioactive diagnosis and treatment medicament based on chemotactic factor receptor CXCR4 polypeptide antagonist |
IN2014KN02752A (en) * | 2012-06-06 | 2015-05-08 | Polyphor Ag | |
US10919938B2 (en) * | 2014-06-06 | 2021-02-16 | Technische Universität München | Modified cyclopentapeptides and uses thereof |
CN109922818B (en) * | 2016-09-06 | 2024-02-20 | 主线生物科学公司 | CXCR4 antagonists and methods of use |
-
2020
- 2020-03-27 JP JP2022545389A patent/JP2023516878A/en active Pending
- 2020-03-27 WO PCT/US2020/025522 patent/WO2021150258A1/en unknown
- 2020-03-27 CN CN202080094623.3A patent/CN115003684A/en active Pending
- 2020-03-27 EP EP20915510.0A patent/EP4097120A4/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080300177A1 (en) * | 2007-05-30 | 2008-12-04 | Wayne David Kohn | Cyclic peptide cxcr4 antagonists |
US20140135381A1 (en) * | 2010-12-29 | 2014-05-15 | Hoffmann-La Roche Inc. | Small molecule conjugates for intracellular delivery of biologically active compounds |
WO2019050564A1 (en) * | 2017-09-05 | 2019-03-14 | Mainline Biosciences | High affinity cxcr4 selective binding conjugate and method for using the same |
Non-Patent Citations (1)
Title |
---|
See also references of EP4097120A4 * |
Also Published As
Publication number | Publication date |
---|---|
CN115003684A (en) | 2022-09-02 |
EP4097120A4 (en) | 2024-05-01 |
JP2023516878A (en) | 2023-04-21 |
WO2021150258A9 (en) | 2021-11-11 |
EP4097120A1 (en) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3679053A1 (en) | High affinity cxcr4 selective binding conjugate and method for using the same | |
JP5358564B2 (en) | Cyclic peptide CXCR4 antagonist | |
KR100668546B1 (en) | Peptides and Compounds That Bind to a Receptor | |
US11883501B2 (en) | Selective CXCR4 binding peptide conjugate and methods for making and using the same | |
US10870681B2 (en) | CXCR4 antagonists and methods of use | |
US10639379B2 (en) | High affinity CXCR4 selective binding conjugate and method for using the same | |
WO2021150258A1 (en) | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same | |
US20240082346A1 (en) | Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same | |
AU2003253258A1 (en) | Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity | |
CN113024635B (en) | Application of stapling peptide compound and pharmaceutical composition thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20915510 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022545389 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020915510 Country of ref document: EP Effective date: 20220826 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |